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ABSTRACT 
 
PROTECTIVE EFFECTS OF PIGMENTATION IN PSEUDOMONAS AERUGINOSA: 
INSIGHTS ON PYOMELANIN PRODUCTION AND INHIBITION BY NTBC 
 
by 
 
Laura M. Ketelboeter 
 
 
The University of Wisconsin-Milwaukee, 2016 
Under the Supervision of Professor Sonia L. Bardy 
 
 
Pyomelanin is an extracellular, reddish-brown pigment produced by several 
environmental and pathogenic bacteria and fungi. It is derived from the 
phenylalanine/tyrosine catabolism pathway and is produced when homogentisate 
(HGA) is secreted from the cell, auto-oxidized, and self-polymerized. Point mutations or 
chromosomal deletions in hmgA, which encodes homogentisate 1,2-dioxygenase, result 
in the accumulation of HGA and subsequent pyomelanin production. My work showed 
that the pyomelanogenic Pseudomonas aeruginosa clinical isolate PA1111 had a 
chromosomal deletion of hmgA, while a second pyomelanogenic clinical isolate, 
DKN343, had a loss of function mutation in HmgA. The 4-hydroxyphenylpyruvate 
dioxygenase (Hpd) inhibiting compound 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC) has been proposed as a treatment for microbial infections by 
pyomelanin producers. NTBC inhibits Hpd by binding irreversibly to the ferrous metal 
center in the active site of the enzyme, which should prevent HGA formation and 
subsequent pyomelanin production. NTBC reduced pyomelanin production in a dose 
dependent manner in both PA1111 and DKN343; DKN343, however, was more 
	 iii 
resistant to NTBC than PA1111. NTBC resistance studies revealed that the multi-drug 
efflux pump MexAB-OprM was responsible for the inherent resistance to NTBC 
observed in DKN343. One of the functions of pyomelanin is resistance to oxidative 
stress, and treatment of PA1111 with NTBC resulted in increased sensitivity to H2O2 
compared to the untreated strain. Additionally, reduction in pyomelanin production with 
NTBC had no effect on PA1111 aminoglycoside minimum inhibitory concentrations, 
which demonstrated that NTBC could possibly be used in conjunction with antibiotics. 
Pyomelanin was involved in persistence of P. aeruginosa in mouse models of infection, 
so I investigated macrophage-based killing of pyomelanogenic P. aeruginosa. My 
results showed little difference in bacterial survival during RAW 264.7 infection between 
pyomelanin producers and non-producers under different test conditions. My work 
provided some data for the potential development of NTBC as a treatment for 
pyomelanogenic microbial infections. NTBC shows some promise as a therapeutic 
agent, but its effectiveness may be limited in organisms with high levels of antimicrobial 
resistance such as P. aeruginosa. Future studies should focus on the prevalence of 
NTBC resistance in other pyomelanogenic organisms to determine the future 
applications of NTBC as an anti-microbial therapy. 
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Chapter One 
Overview of pyomelanin production and anti-virulence treatment in 
Pseudomonas aeruginosa 	 	
	 2 
1.1 Pseudomonas aeruginosa 
 
 Pseudomonas aeruginosa is a Gram negative bacterium in the Gamma 
Proteobacteria class. It is rod shaped and has a single polar flagellum for swimming 
motility. P. aeruginosa is found in diverse ecological environments including soil, 
organic matter, water, plants, animals, and moist surfaces, and has the ability to form 
biofilms (1). Additionally, P. aeruginosa is an opportunistic pathogen and is a common 
cause of both acute and chronic infections in individuals who are compromised. P. 
aeruginosa frequently colonizes the lungs of cystic fibrosis (CF) patients and forms 
biofilms that are very difficult to eradicate, leading to persistent bacterial infections (2). 
In addition, P. aeruginosa is frequently isolated from burn patients (3, 4), where it 
causes an acute infection. P. aeruginosa has been implicated in a variety of other 
infections, including pneumonia and upper respiratory tract infections, urinary tract 
infections, eye infections such as keratitis, and infections in various other parts of the 
body (1). 
 The persistence of P. aeruginosa infections is due, in part, to different 
mechanisms of resistance to antimicrobial agents. Low outer membrane permeability 
can prevent antimicrobial agents from entering the cell (5). Chromosomally encoded β-
lactamases can also inactivate β-lactam antibiotics (1). Biofilm formation results in 
increased resistance to various antimicrobial agents (1, 6). This is likely due to the fact 
that cells in a biofilm display heterogeneous physiology depending on where they are 
located (7), and slow growing or dormant cells in a biofilm may be a resistant population 
because many antimicrobial agents are dependent on actively metabolizing cells to be 
effective (8). Additionally, multidrug efflux pumps have broad specificity for antibiotics 
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and other antimicrobial agents and function in transporting these compounds from the 
cell (9). These different resistance mechanisms make it difficult to treat P. aeruginosa 
infections. 
 P. aeruginosa has 12 different resistance nodulation division (RND) efflux 
pumps, four of which are known to contribute to antibiotic resistance (MexAB-OprM, 
MexCD-OprJ, MexEF-OprN, and MexXY-OprM) (1). MexAB-OprM is constitutively 
expressed in P. aeruginosa, and hyperexpression of mexAB-oprM has been observed 
in multi-drug resistant clinical isolates (6). This hyperexpression is frequently due to 
mutations in mexR, which encodes the MexR repressor for the mexAB-oprM operon 
(10). Two other regulators of mexAB-oprM transcription have been identified. Mutations 
in nalD can lead to hyperexpression of MexAB-OprM and multi-drug resistance in both 
laboratory and clinical isolates of P. aeruginosa (11). NalD has also been shown to bind 
to a second mexAB-oprM promoter, and a nalD mutant showed increased expression 
from that promoter (12). Novobiocin can bind to NalD, causing it to dissociate from the 
mexAB-oprM promoter, and result in increased mexAB-oprM expression (13) 
Additionally, nalC mutants showed hyperexpression of mexAB-oprM (14). NalC 
represses expression of armR, which encodes the anti-MexR repressor that binds to 
MexR and prevents MexR from binding to the mexAB-oprM promoter, thereby resulting 
in hyperexpression of mexAB-oprM (15). Pentachlorophenol induces expression of 
armR via modulation of NalC repressor activity (15). Additionally, oxidative stress can 
increase expression of mexAB-oprM (16). Since MexAB-OprM is constitutively 
expressed, it contributes to intrinsic resistance to antimicrobial agents. It is able to 
extrude several classes of antibiotics, as well as dyes, detergents, organic solvents, 
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fatty acid synthesis inhibitors, and homoserine lactone (13), which demonstrates that it 
has broad substrate specificity. 
 Other multi-drug efflux pumps can contribute to antibiotic resistance. MexXY is 
induced in response to aminoglycoside, tetracycline, and macrolide antibiotics, as well 
as oxidative stress (16, 17). Additionally, clinical isolates can express both MexAB-
OprM and MexXY multi-drug efflux pumps (17). Nitrosative stress and chloramphenicol 
are capable of inducing expression of mexEF-oprN (16). Induction of mexCD-oprJ 
expression occurs in response to membrane damaging agents including biocides, dyes, 
detergents, organic solvents, and cationic antimicrobial peptides such as polymyxin B 
and colistin (16). MexCD-OprJ and MexEF-OprN are not usually expressed in wild type 
P. aeruginosa under normal laboratory conditions, but are expressed in nfxB and nfxC 
mutants, respectively (18). The fact that multi-drug efflux pump expression can be 
induced by different stressors indicates that these pumps may not have evolved to 
extrude antimicrobial agents and they likely play a role in stress response. 
P. aeruginosa has a large genome, with several variable sections containing 
genes that are involved in producing a variety of virulence factors, including secreted 
proteins, toxins, and pigments (19). The four different pigments that can be produced by 
P. aeruginosa are pyocyanin, pyoverdine, pyorubrin, and pyomelanin. Pyocyanin is a 
blue-green pigment and is produced in 90-95 percent of P. aeruginosa isolates (20). 
This pigment is a phenazine and redox active secondary metabolite that functions as a 
virulence factor (20). Pyoverdine is a yellow-green pigment that functions as a 
siderophore for iron acquisition (21). This pigment is widely distributed in Pseudomonas 
species and over 60 pyoverdines have been identified to date (22). Pyorubrin is a red 
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pigment that is rarely isolated and infrequently studied in P. aeruginosa (23, 24). 
Pyomelanin is a reddish-brown pigment produced in some strains of P. aeruginosa (25). 
This pigment is one of four types of melanin and will be described in detail in this work. 
 
1.2 Types of melanin 
 
 Melanin production has been identified in many organisms, including animals, 
bacteria, and fungi. In general, melanin pigments are composed of polymerized 
phenolic or indolic compounds with an undefined structure that are dark in color (26, 
27). These pigments are negatively charged and hydrophobic with a high molecular 
weight (26, 27). Melanins are also susceptible to bleaching by oxidizing agents, 
resistant to concentrated acid, and insoluble in aqueous or organic fluids (26, 27). 
Melanin synthesis occurs through either phenoloxidases, such as tyrosinases, laccases, 
and catacholases, or the polyketide synthase pathway (27). In bacteria, tyrosinases are 
more common in melanin production than laccases (27). Melanin may provide a survival 
advantage in the various environments encountered by bacteria and fungi and has been 
associated with virulence of pathogenic organisms in hosts (26, 27). 
Four types of melanin can be produced including eumelanin, pheomelanin, 
dihydroxynaphthalene (DHN) melanin, and pyomelanin. Eumelanin is usually black or 
brown and is formed from 3,4-dihydroxyphenyalanine (DOPA) by phenoloxidases (26, 
28). This type of melanin can be found in bacteria, fungi, and animals (28-32). 
Pheomelanin is red or yellow and is formed by the incorporation of cysteine with DOPA 
(26, 28). Animals typically produce this type of melanin (28, 32). DHN-melanin is formed 
from acetyl-CoA and malonyl-CoA via the polyketide synthase pathway and is usually 
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black or brown (26, 33). This type of melanin is commonly found in fungi (31). 
Pyomelanin is generally reddish-brown and is formed from homogentisate during 
tyrosine catabolism (34). Both fungi and bacteria produce this type of melanin (27, 35). 
 
1.3 Pyomelanin production 
 
Pyomelanin has been reported in many clinical and environmental bacterial and 
fungal species, including P. aeruginosa, Burkholderia cepacia complex, Vibrio cholerae, 
Legionella pneumophila, Shewanella algae, Bacillus anthracis, Aeromonas media, 
Acinetobacter baumannii, Sinorhizobium meliloti, Streptomyces coelicolor, Alteromonas 
stellipolaris, Aspergillus fumigatus, Sporothrix sp., and Penicillium chrysogenum (25, 
36-49). In these strains, pyomelanin is either naturally produced in the wild type strain or 
is the result of mutation or deletion of genes involved in tyrosine catabolism. Natural 
production of pyomelanin in bacterial and fungal species is important in allowing us to 
study how the pigment is produced under different environmental conditions. 
Inactivation of genes involved in pyomelanin production via mutation or deletion can 
allow us to elucidate the functions of pyomelanin, as well as examine the individual 
contributions of genes in tyrosine catabolism to pigment production. 
 
1.3.1 Phenylalanine and tyrosine catabolism pathway 
 
Pyomelanin is a negatively charged, extracellular, reddish-brown pigment derived 
from the phenylalanine and tyrosine catabolism pathway (Figure 1.1) (34, 50). The 
tyrosine catabolism pathway is conserved in almost all aerobic organisms and is used to 
acquire energy from tyrosine breakdown (51). In this pathway, phenylalanine is first 
	 7 
L-tyrosine 
4-hydroxyphenylpyruvate 
homogentisate (HGA) 
maleylacetoacetate 
fumarylacetoacetate 
fumarate acetoacetate 
PhhC 
Hpd 
HmgA 
MaiA 
FahA 
Secretion from cell,  
auto-oxidation, and  
self-polymerization 
Pyomelanin 
HatABCDE 
L-phenylalanine 
PhhAB 
acetoacetyl-CoA 
acetyl-CoA 
DhcAB 
AtoB 
Figure 1.1. Phenylalanine/tyrosine catabolism pathway in P. aeruginosa. PhhA, phenylalanine-4-
hydroxylase; PhhB, pterin-4-α-carbinolamine dehydratase; PhhC, aromatic amino acid 
aminotransferase; Hpd, 4-hydroxyphenylpyruvate dioxygenase; HmgA, homogentisate 1,2-
dioxygenase; MaiA, maleylacetoacetate isomerase; FahA, fumarylacetoacetase; DhcAB, 
dehydrocarnitine CoA transferase, subunits A and B; AtoB, acetyl-CoA acetyltransferase; HatABCDE, 
HatABCDE ABC transporter. P. aeruginosa nomenclature is used (Pseudomonas Genome Database 
http://www.pseudomonas.com). 
	 8 
converted to tyrosine by phenylalanine-4-hydroxylase (PhhA) and pterin-4-alpha-
carbinolamine dehydratase (PhhB). Tyrosine is then converted to 4-
hydroxyphenylpyruvate by an aromatic amino acid aminotransferase (PhhC or TyrB). 
Next, 4-hydroxyphenylpyruvate is converted to homogentisate (HGA) by 4-
hydroxyphenylpyruvate dioxygenase (Hpd). After HGA is formed, it is converted to 
maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). Maleylacetoacetate is 
converted to fumarylacetoacetate by maleylacetoacetate isomerase (MaiA or HmgC). In 
the next step in the pathway, fumarylacetoacetate is split into fumarate and 
acetoacetate by fumarylacetoacetase (FahA or HmgB). The last steps of the pathway 
involve conversion of acetoacetate into acetoacetyl-CoA by the dehydrocarnitine CoA 
transferase, subunits A and B (DhcA and DhcB), and finally the formation of acetyl-CoA 
from acetoacetyl-CoA by the acetyl-CoA acetyltransferase (AtoB) (52). The end 
products of tyrosine catabolism go into the TCA cycle (45, 53). 
Pyomelanin production occurs when there is a defect in the tyrosine catabolism 
pathway, either through mutations or deletions of key genes, or reduced enzyme activity 
for the enzymes in the latter part of the pathway (HmgA, MaiA, and FahA) compared to 
enzymes in the upper part of the pathway (54-56). In P. aeruginosa, it was found that 
strains containing mutations in maiA and fahA did not produce pyomelanin, which 
suggested that inactivation of hmgA was the only cause of pyomelanin production in 
that organism (56). Several proteins in the phenylalanine and tyrosine catabolism 
pathway have been implicated in pyomelanin production, and these proteins will be 
discussed in detail below. 
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1.3.2 Homogentisate 1,2-dioxygenase (HmgA) 
 
One of the major proteins that impacts pyomelanin production is HmgA, which is 
responsible for converting HGA to maleylacetoacetate. In P. aeruginosa, defects in the 
hmgA gene, either through chromosomal deletions or point mutations, result in 
pyomelanin production because the tyrosine catabolism pathway stalls and HGA 
accumulates (55, 56). Pyomelanin is produced when HGA is secreted from the cell, 
leading to auto-oxidation and self-polymerization (34, 56, 57). Secretion of HGA occurs 
via the HatABCDE transport system, and defects in this transport system result in 
reduced pyomelanin production (57). 
Deletions of hmgA and potential defects in regulation of hmgA expression have 
been identified in various strains of P. aeruginosa that produce pyomelanin. In the P. 
aeruginosa pyomelanogenic clinical isolate PA1111, which was isolated from an acute 
infection in a burn patient, a chromosomal deletion of hmgA was identified and 
determined to be the cause of pyomelanin production in that strain (58, 59). Additional 
studies of two clinical pyomelanogenic P. aeruginosa strains from CF patients showed 
that one strain contained a deletion of hmgA, while the other strain had no mutations or 
deletions of hmgA, which indicated that mutations in a transcriptional regulator may be 
responsible for pigment production in that strain (56). Interestingly, downregulation of 
hmgA in a chronic isolate of P. aeruginosa Australian epidemic strain-1 (AES-1) from a 
CF lung did not result in pyomelanin production (60), which indicated that there was 
enough functional HmgA produced to prevent pigment formation even when hmgA 
expression was downregulated. These results demonstrate that chromosomal deletions 
of hmgA may be a frequent cause for pyomelanin production in P. aeruginosa, and it 
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can occur in isolates from both acute and chronic infections. Regulation of hmgA 
expression may also be important in pigment production, as downregulation of hmgA 
did not result in pigment production, while a strain with a possible defect in a 
transcriptional regulator did show pyomelanin production. 
Studies in several other bacteria have revealed defects in hmgA as a cause for 
pyomelanin production. In some strains of V. cholerae, pyomelanin can be produced 
under normal experimental growth conditions. Analysis of these strains revealed that 
they contained either a 15 or 10 base pair (bp) deletion mutation in homogentisate 
oxygenase, and the 15 bp deletion was conserved in six O139 strains that were studied 
(61). Additionally, in a Burkholderia cenocepacia pyomelanogenic CF clinical isolate a 
single point mutation in hmgA resulted in an amino acid change from a glycine to an 
arginine at residue 378, and this mutation was conserved in three of four pigmented B. 
cepacia complex strains (62). The G378R mutation in B. cenocepacia was located in 
the iron cofactor binding region of HmgA, which could affect iron binding and 
subsequent enzyme function (62). In A. media WS, it was recently reported that 
pyomelanin is the major melanin produced in this strain, not L-DOPA melanin as 
previously thought, and the hmgA gene was disrupted by an insertion of a different gene 
in the opposite orientation (42). Conservation of deletions and mutations in hmgA is 
important because it demonstrates stability of a defect across several strains of 
bacteria, and could also represent a hot spot for mutations. Additionally, conservation of 
mutations could represent horizontal gene transfer between different bacteria, which 
would explain why they have the same mutation or deletion.  
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Pyomelanin production has also been observed in several other bacterial and 
fungal strains after transposon mutagenesis or in-frame deletion of hmgA, including B. 
anthracis, Vibrio campbellii, S. meliloti, Pseudomonas chlororaphis, and A. fumigatus 
(41, 44, 47, 63, 64). Creation of stable mutations in hmgA for bacteria that do not 
produce pyomelanin in the wild type strain can allow us to study mechanisms of 
pigment production in different bacteria, as well as allow us to study the functions of 
pyomelanin in these bacteria. 
 
1.3.3 4-hydroxyphenylpyruvate dioxygenase (Hpd) 
 
The second major protein involved in pyomelanin production is Hpd, the enzyme 
responsible for the production of HGA from 4-hydroxyphenylpyruvate. Transposon 
mutagenesis or deletion of hpd led to an abolishment of pyomelanin production in B. 
cenocepacia, L. pneumophila, P. aeruginosa, A. media WS, and A. fumigatus (39, 42, 
47, 57, 62, 65). The lack of pigmentation in these hpd mutant strains demonstrates the 
importance of Hpd in the production of the pyomelanin precursor molecule HGA. If Hpd 
is not present, HGA cannot form, and pyomelanin production will not occur.  
Additionally, expression of Hpd from the bacterial species A. stellipolaris LMG 
21856, L. pneumophila, B. cenocepacia, and Streptomyces avermitilis, as well as the 
archaeon Picrophilus torridus, in Escherichia coli resulted in pyomelanin production (36, 
46, 66-68). E. coli does not possess genes for the tyrosine catabolism pathway; 
therefore, expression of recombinant Hpd in E. coli produces HGA, which can oxidize 
and polymerize to form pyomelanin. These results emphasize the importance of Hpd in 
pyomelanin production and also show that Hpd from different microbial species are 
	 12 
functional in E. coli. The ability to produce functional recombinant Hpd in E. coli can 
allow researchers to further examine the functions and characteristics of this protein 
independent of the organism from which it was originally isolated. 
 
1.3.4 Other proteins implicated in pyomelanin production 
 
Additional proteins involved in pyomelanin production include phenylalanine-4-
hydroxylase (PhhA) and pterin-4-alpha-carbinolamine dehydratase (PhhB), which 
convert phenylalanine to tyrosine, and the aromatic amino acid aminotransferase 
(PhhC/TyrB), which converts tyrosine to 4-hydroxyphenylpyruvate. phhA, phhB, and 
phhC transposon mutants in a pyomelanogenic P. aeruginosa strain showed no 
pigment production (57). In L. pneumophila, phhA mutants also showed reduced 
pigmentation during growth (69). Additionally, phhA and tyrB mutants in A. media WS 
showed reduced pigment production (42). These results show a functional role for 
proteins in the upper part of the phenylalanine/tyrosine catabolism pathway in 
pyomelanin production. 
The conversion of phenylalanine to tyrosine by PhhAB is important in pyomelanin 
production because in the absence of tyrosine in the environment, phenylalanine must 
be converted to tyrosine for the phenylalanine/tyrosine catabolism pathway to eventually 
produce the HGA needed for pigment production. The phhA mutants that showed 
reduced pigmentation may have the ability to obtain tyrosine from the environment 
when PhhA is non-functional, thereby allowing them to produce some HGA through 
tyrosine catabolism. The phhA mutants that showed no pigmentation could exhibit 
reduced uptake of tyrosine from the environment compared to the phhA mutants that 
	 13 
did show some pigmentation, which would account for the differences in pyomelanin 
production that were observed. It is also possible that the phhA mutants can obtain 
tyrosine through aromatic amino acid biosynthesis, which could then allow them to 
produce some pigment. Pseudomonas putida is capable of phenylalanine and tyrosine 
biosynthesis from chorismate via chorismate mutase (PheA) and bifunctional 
cyclohexadienyl dehydrogenase/3-phosphoshikimate 1-carboxyvinyltransferase 
(PP1770/TyrA) (70). P. aeruginosa has a homolog for PheA (87.19 percent identity), but 
3-phosphoshikimate 1-carboxyvinyltransferase prephenate dehydrogenase is a 
pseudogene (71). 
The conversion of tyrosine to 4-hydroxyphenylpyruvate by PhhC/TyrB is 
important because 4-hydroxyphenylpyruvate is needed to produce HGA. The lack of 
pigmentation in phhC mutants suggested that the bacteria do not possess additional 
aromatic amino acid aminotransferases that can convert tyrosine into 4-
hydroxyphenylpyruvate. Reduced pigmentation in tyrB mutants, however, suggested 
that there could be an additional enzyme functioning as an aromatic amino acid 
aminotransferase that can contribute to the conversion of tyrosine to 4-
hydroxyphenylpyruvate, which would allow some HGA to be produced. 
Other proteins may also be involved in pyomelanin production. In P. putida, 
deletion of two genes encoding an acyl-CoA transferase involved in acetoacetate 
degradation resulted in pigment production (53), which demonstrated that the proteins 
encoded by those genes are important for a functional tyrosine catabolism pathway. 
The homologous proteins for the P. putida acyl-CoA transferase in P. aeruginosa are 
dehydrocarnitine CoA transferase, subunits A and B (DhcA, 85.78 percent identity; 
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DhcB, 90.37 percent identity) (71). Although it has not been demonstrated that DhcA 
and DhcB are involved in pyomelanin production in P. aeruginosa, it is certainly possible 
that they could be involved since the homologous proteins in the closely related 
organism P. putida have been implicated in pigmentation. 
 
1.3.5 Laboratory growth conditions 
 
Laboratory growth conditions may also affect pyomelanin production. Many 
organisms require the addition of tyrosine to growth medium in order to produce 
pyomelanin. In S. meliloti, addition of tyrosine to the medium enhanced pyomelanin 
production (44). Additionally, in V. cholerae, pyomelanin was produced in low nutrient 
conditions when tyrosine was supplemented, but never in rich media (54). Tyrosine 
addition to media enhanced pigment production in L. pneumophila (66). In P. 
chrysogenum, pyomelanin was produced when tyrosine was included in the growth 
medium, and HGA was detected only in cultures grown with tyrosine (49). Pyomelanin 
production in A. fumigatus occurred when strains were grown on media containing 
tyrosine (47). Sporothrix complex species were also able to produce pyomelanin at 
varying levels when they were grown in minimal media containing tyrosine (48). These 
results demonstrate the importance of including tyrosine in growth medium. Additionally, 
adding a specific concentration of tyrosine to a minimal growth medium can help 
eliminate some of the variability in experimental results and show that pigment is 
produced only under certain conditions. It is also possible that the concentration of 
tyrosine in a rich medium is not high enough to induce pigment production in some 
strains of bacteria and fungi. 
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1.4 Regulation of pyomelanin production 
 
In P. aeruginosa, the genes for phenylalanine/tyrosine catabolism are found in 
several operons that are scattered in the genome (Figure 1.2). The phhABC genes are 
found in an operon, and the transcriptional regulator phhR is divergently transcribed (50, 
71). hpd is not in an operon, but it is located in close proximity to phhABC (71). The 
hmgA-fahA-maiA genes are also found in an operon, and the probable transcriptional 
regulator gene PA2010, which is homologous to the P. putida repressor hmgR that is 
known to regulate the hmg operon, is divergently transcribed (50, 71). The dhcAB 
genes form an operon, with atoB, which encodes the acetyl-CoA acetyltransferase, 
directly downstream but not part of the operon, and the transcriptional regulator dhcR is 
divergently transcribed (71). Organization of operons and names of 
phenylalanine/tyrosine catabolism genes vary in different organisms, including in other 
Pseudomonas species (50). 
Several proteins have been implicated in the regulation of phenylalanine/tyrosine 
catabolism in various organisms, including Crc, TyrR/PhhR, and HmgR. Both global and 
operon specific regulators have been identified that control phenylalanine/tyrosine 
catabolism, which may be important in pyomelanin production. Regulators found in 
Pseudomonas species will be discussed in the following sections. 
 
1.4.1 Crc global regulator 
 
 Crc is a global regulator that controls expression of genes from aromatic 
compound catabolism pathways. In P. putida and P. aeruginosa, Crc acts as a master 
regulator of carbon metabolism (72). Studies in P. putida have shown that Crc 
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Figure 1.2. Organization of genes for phenylalanine/tyrosine catabolism in P. aeruginosa. Operons 
are formed for phhABC, hmgA-fahA-maiA, and dhcAB. phhR and dhcR are genes for regulatory 
proteins of their respective operons. PA2010 is predicted to be a homolog of hmgR from P. putida, 
which is a gene for a regulatory protein of the hmgA operon. Genes for regulatory proteins are in red. 
P. aeruginosa nomenclature and PA numbers from PAO1 are used (Pseudomonas Genome Database 
http://www.pseudomonas.com). Arrow size and distance between genes is not drawn to scale. 
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represses expression of hpd, hmgA, and mai, which was indicated by increased mRNA 
levels for those genes in a crc mutant compared to the wild type strain (72). As Crc is 
not known to bind DNA, it is unknown if Crc affects transcription of the genes it 
regulates directly or indirectly (72). Conflicting reports about the binding target for Crc 
have been reported. In one study, Crc from P. putida was found to bind to mRNA and 
repress translation (73), while a later study showed that Crc from P. aeruginosa did not 
bind to RNA (74). Crc appears to be an important regulator of gene expression in P. 
putida, and it is likely that similarities exist in P. aeruginosa. Additionally, in a 
pyomelanogenic P. aeruginosa strain, a crc transposon mutant showed reduced 
pyomelanin production (57), which indicates that Crc may have a role in pigment 
formation by regulating expression of genes involved in tyrosine catabolism. 
 
1.4.2 TyrR and PhhR transcriptional regulators 
 
Another regulator for phenylalanine/tyrosine catabolism genes is TyrR/PhhR. In 
E. coli, TyrR acts as both a repressor and an activator of DNA transcription. To activate 
transcription, TryR interacts with the C-terminal region of the α-subunit of RNA 
polymerase (αCTD) when aromatic amino acids are present and binds to DNA 
upstream of the promoters for genes that encode aromatic amino acid transporters (75). 
In E. coli, TyrB is an aromatic amino acid aminotransferase involved in the biosynthesis 
of tyrosine and phenylalanine (76). TyrR represses tyrB transcription in the presence of 
tyrosine or phenylalanine. TyrR forms hexamers in the presence of tyrosine, which bind 
to DNA and prevent open complex formation during initiation of transcription (76). When 
phenylalanine is present, TyrR dimers or tetramers bind to DNA and an open complex 
	 18 
can form, but RNA polymerase cannot exit the promoter (76). Both of these 
mechanisms of repression prevent tyrB transcription. The Pseudomonas TyrR homolog 
is PhhR (77), which has similar regulatory functions in both P. putida and P. aeruginosa, 
with a few differences. 
PhhR is a global regulator in P. putida that activates genes for phenylalanine 
degradation (53). In both P. aeruginosa and P. putida, PhhR induced the phhA, hpd, 
hmgA, and dhcA (PP3122 in P. putida) transcriptional units in response to 
phenylalanine (52, 53, 77). Additionally, the expression of phenylalanine/tyrosine 
catabolism genes was downregulated in a phhR mutant strain compared to the wild type 
strain (52, 53). phhR expression was also induced in the presence of aromatic amino 
acids, and P. putida PhhR appeared to negatively regulate phhR gene expression (52, 
53). These results show that PhhR is necessary for transcription of genes involved in 
phenylalanine/tyrosine catabolism, and aromatic amino acids are necessary for 
induction of gene transcription. In addition, a phhR transposon mutant in a P. 
aeruginosa pyomelanin producer showed abolishment of pigmentation (57), which 
indicates a functional role for PhhR in pyomelanin production. This is likely due to 
downregulation of phenylalanine/tyrosine catabolism gene expression in phhR mutants, 
which could prevent pigment production because the pyomelanin precursor molecule 
HGA would not be produced. 
 Experimental evidence has shown that PhhR binds to the phhA, hpd, and dhcA 
(PP3122) promoters in P. aeruginosa and P. putida, and also to the hmgA promoter in 
P. putida, but not in P. aeruginosa (52, 53). The experimental data for PhhR promoter 
binding matches the predictions for PhhR binding sites in the promoters of those 
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transcriptional units. Additionally, in P. aeruginosa it was found that PhhR mainly 
regulates transcription from σ54 promoters, not σ70 promoters as seen in E. coli TyrR 
(52, 77). Potential σ54 binding sites were identified in P. aeruginosa upstream of phhA, 
hpd, and dhcA, but not hmgA (52), which corresponds with the identification of PhhR 
binding sites upstream of the same genes and provides further evidence that those 
transcriptional units are regulated by PhhR. 
Additional differences between PhhR from P. putida and P. aeruginosa have 
been identified. In P. putida, genes for aromatic amino acid biosynthesis were 
repressed in the presence of phenylalanine (53). In P. aeruginosa, PhhR did not control 
expression of biosynthesis genes for aromatic amino acids (52). Overall, there are many 
similarities between PhhR from the closely related species P. aeruginosa and P. putida, 
but there are some differences. 
 
1.4.3 HmgR transcriptional repressor 
 
A third regulator for tyrosine catabolism genes is HmgR. HmgR is an IclR-type 
regulator that functions as a repressor for hmgABC gene expression in P. putida, and 
the homologous protein PA2010 has been identified in P. aeruginosa (50). Studies of 
HmgR function have shown that the protein binds to the hmg promoter in a region that 
partially overlaps the ribosome binding site for hmgA to repress transcription of 
hmgABC in the absence of HGA (50). HGA inhibited HmgR binding to the hmg 
promoter, and a hmgR mutant strain constitutively produced HmgA in normal amounts 
(50). These studies show that HmgR is important for repression of hmgABC gene 
expression in P. putida, and is likely to be important in P. aeruginosa as well, as the 
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hmgA promoter in P. aeruginosa contains a potential HmgR binding site (52). Because 
P. putida and P. aeruginosa are closely related organisms, it is expected that HmgR 
would have a similar function in P. aeruginosa. 
HmgR repression can potentially explain PhhR regulation of hmgA. As described 
above, PhhR regulated hmgA expression in P. aeruginosa, but there was no PhhR 
binding site (52). This phenomenon can be explained by the presence or absence of 
Hpd and HGA in the cell, as well as the HmgR binding site in the hmgA promoter. Since 
hpd expression is controlled by PhhR, if PhhR activates hpd when phenylalanine is 
present, the Hpd protein will be produced and HGA will subsequently be formed (52). 
HGA can then bind to HmgR, which prevents HmgR from binding to the hmgA 
promoter, and finally allows for expression of hmgA (52). PhhR indirectly regulates 
hmgA expression through HmgR in P. aeruginosa, which adds to the complexity of 
regulation of phenylalanine/tyrosine catabolism gene expression, and also pyomelanin 
production. Interestingly, in P. putida, both PhhR and HmgR directly regulate hmgA 
expression, as binding sites for both regulators have been identified in the promoter for 
hmgA and experiments have shown regulation of hmgA transcription by PhhR and 
HmgR. This demonstrates that there can be differences in regulation by two closely 
related species. 
 
1.5 Functions of pyomelanin 
Microbes encounter a variety of conditions in their natural habitats, so it is 
necessary to have mechanisms that will allow them survive variations in the 
environment. One of these mechanisms is to produce pigments, such as pyomelanin. 
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Pyomelanin has several functions that may help bacteria or fungi survive in host 
organisms or the environment. These functions will be discussed in detail in the 
following sections. 
 
1.5.1 Protection from oxidative and UV stress 
Pyomelanin provides protection from oxidative stress in some bacterial and 
fungal species. In P. aeruginosa, pyomelanin protected cells from H2O2 induced 
oxidative stress in both a plate based assay and a viable count assay (56, 58). 
Additionally, P. aeruginosa pyomelanin containing supernatant was able to protect non-
pigmented wild type cells from H2O2 (56). Pyomelanin produced by P. aeruginosa was 
also able to protect cells from photodynamically induced oxidative stress, which can 
generate singlet oxygen, superoxide anion radical, H2O2, and hydroxyl radical, by 
scavenging radicals and quenching singlet oxygen (78). These results demonstrate that 
pyomelanin produced by P. aeruginosa is able to provide protection from oxidative 
stress under a variety of different test conditions, which is important because bacteria 
may encounter different conditions in the various environments they inhabit. 
Other bacterial and fungal species have also demonstrated resistance to 
oxidative stress when pyomelanin was present. In V. campbellii, pyomelanin containing 
supernatant was able to protect non-pigmented wild type cells from H2O2 induced 
oxidative stress (63); this protective effect was also seen in P. aeruginosa. Non-
pigmented strains of B. cenocepacia were more sensitive to H2O2 in a disc diffusion 
assay, as well as to extracellular superoxide generated by the xanthine/xanthine 
oxidase reaction, compared to strains that produced pyomelanin (36). In A. fumigatus, 
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pyomelanin producers were more resistant to H2O2 induced oxidative stress than non-
producers in an agar plate diffusion assay (47). Pyomelanin provided protection from 
both oxygen and nitrogen derived oxidants in Sporothrix sp. (48). In B. anthracis, 
however, pyomelanin did not provide protection from oxidative stress in a H2O2 disc 
diffusion assay, or when a non-pigmented strain was suspended in supernatants from a 
pyomelanin producer followed by exposure to H2O2 (41). These results show that 
pyomelanin frequently provides protection from oxidative stress in bacteria and fungi, 
but this protection is not universal in all organisms that produce pyomelanin. 
Additionally, pyomelanin can provide resistance to UV stress that may be 
encountered by bacteria and fungi in the environment. In B. anthracis, pyomelanin 
producers showed increased survival compared to non-pigmented strains after UV 
irradiation (41). L. pneumophila with a mutation in the hpd homolog lly, which eliminated 
pyomelanin production in the bacteria, was more sensitive to light than a pigmented 
strain (66). In Sporothrix sp., pyomelanin production provided protection from UV light 
(48). The ability of pyomelanin to protect against UV stress is important because UV 
radiation can cause mutations in DNA that can be detrimental for the organism if they 
cannot be repaired (79). These results show that pyomelanin can protect bacteria and 
fungi from stresses they may encounter in the environment, whether it is in a host 
during infection (oxidative stress) or in the natural environment (UV stress), which could 
be detrimental for their survival. 
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1.5.2 Iron reduction and acquisition 
 
Pyomelanin also functions in electron transfer and metal reduction. Studies in S. 
algae BrY have shown that pyomelanin can act as a soluble electron shuttle for iron 
oxide reduction and as a terminal electron acceptor (40). S. algae BrY cells that 
produced pyomelanin, as well as non-pyomelanogenic cells with added pyomelanin, 
were able to reduce more ferric oxide than cells that did not produce pyomelanin (80). 
These results indicate that it is the presence of pyomelanin that is important for 
increased iron reduction, not necessarily the ability of the organism to produce 
pyomelanin itself. In L. pneumophila, pyomelanin had ferric reductase activity (39). A 
hmgA mutant that produced increased amounts of pyomelanin had higher ferric 
reductase activity than wild type L. pneumophila, which produced low levels of 
pyomelanin, while a lly mutant (hpd mutant) that was null for pyomelanin production had 
lower ferric reductase activity than wild type (39). This data indicates that increased 
amounts of pyomelanin production resulted in increased iron reduction. 
Pyomelanin is also involved in iron uptake, as well as enhancement of bacterial 
growth in low iron conditions. Studies of pyomelanin in L. pneumophila have shown that 
both pyomelanin and the pyomelanin precursor molecule HGA are involved in iron 
reduction, and the bacteria can take up the reduced iron (81). Pyomelanin also 
increased growth of L. pneumophila in low iron conditions, which was likely due to the 
association of iron with pyomelanin, which could lead to increased iron assimilation (81). 
L. pneumophila also produces siderophores for acquiring iron, and a hyperpigmented 
hmgA transposon mutant produced lower levels of siderophores than the wild type, 
while a siderophore mutant produced more pyomelanin than wild type, which indicates 
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that pyomelanin is involved in iron assimilation (81). These data demonstrate that L. 
pneumophila has different methods for acquiring iron, and if one mechanism is inactive, 
the other mechanism can compensate. Although it has not been tested in P. 
aeruginosa, it is possible a similar mechanism for acquiring iron could exist in that 
organism since it is capable of producing both pyomelanin and siderophores. 
Enzymes involved in pyomelanin production are also affected by iron 
concentrations. In L. pneumophila, PhhA was involved in pyomelanin production and 
growth in low tyrosine media (69). PhhA has an iron cofactor in its active site and its 
enzymatic activity required iron, but high concentrations of iron also inhibited activity 
(69). In S. algae BrY the rate of pyomelanin production and the amount of pyomelanin 
produced decreased when iron concentrations were higher than the optimum (82). 
These results demonstrate that iron is necessary for pyomelanin production and that 
pyomelanin itself is capable of providing bacteria with iron needed for growth and other 
functions. The concentration of iron is important, however, since the presence of too 
much iron can inhibit enzymatic function. 
 
1.5.3 Antibiotic resistance 
 
Resistance to antibiotics and other antimicrobial drugs can be a major problem 
when treating bacterial and fungal infections. Various studies have shown that melanin 
can bind to some antibiotics and antifungal drugs, thereby reducing the activity of those 
drugs (26). Isotherm analysis of gentamicin and synthetic melanin revealed high levels 
of binding between those compounds (83). Additionally, interactions between 
tobramycin and synthetic melanin resulted in a decrease in antibiotic activity under 
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certain conditions (84). Increased resistance to specific antibiotics was observed in 
pyomelanogenic Stenotrophomonas maltophilia compared to non-pigmented strains 
(85). In Sporothrix sp., pyomelanin production resulted in increased resistance to the 
antifungal antibiotic amphotericin B (48). In a second study in Sporothrix sp., 
pyomelanin provided protection from the antifungal drug terbinafine during a time-kill 
assay (86). These studies all reveal a role for melanin in antimicrobial resistance. 
In P. aeruginosa, it was reported that pyomelanin producing strains were more 
sensitive to antibiotics than non-pyomelanogenic strains (24, 25, 87). In these studies, 
several different classes of antibiotics were tested, including aminoglycosides, β-
lactams, and polymyxins. These data conflict with the studies presented above that 
showed reduced efficacy of antimicrobials in the presence of both synthetic melanin and 
pyomelanin. 
Recent studies in P. aeruginosa, however, reported no differences in sensitivity 
to aminoglycoside, cephalosporin, β-lactam, and fluoroquinolone antibiotics in 
pyomelanin producers compared to non-producers (56, 58). In A. baumannii, 
pyomelanogenic clinical isolates were resistant to antibiotics, and treatment with 
sulcotrione, an inhibitor of the tyrosine catabolism pathway, reduced pigment production 
but this reduction in pigment production had no effect on antibiotic resistance (43). 
These results show that pyomelanin production in A. baumannii, like P. aeruginosa, 
does not appear to have an effect on antibiotic resistance. 
These conflicting reports about the effects of pyomelanin and other types of 
melanin on antibiotic sensitivity make it difficult to draw conclusions. Taken together, 
these results suggest that pyomelanin production has little effect on antibiotic resistance 
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in bacteria, but may have an effect on antibiotic resistance in fungi. A limitation of 
antibiotic sensitivity assays is that many of them are performed by broth microdilution, 
which uses diluted bacterial cultures, so little preformed pyomelanin may be present at 
the start of the assay, which could affect the results if one wants to determine the 
effects of pyomelanin on antibiotic resistance. Broth microdilution may show that 
pyomelanin has no effect on antimicrobial resistance when there could actually be 
resistance if a different type of assay, such as a time-killing assay, was performed. In a 
time-killing assay, microbes are exposed to 2x minimum inhibitory concentration (MIC) 
of antimicrobial agents and viable counts are determined at several time points (86). 
This type of assay could potentially allow the researcher to start with higher levels of 
preformed pyomelanin at the beginning of the assay, which may have an effect on the 
antibiotic resistance results. 
 
1.5.4 Infection persistence and virulence 
 
Pyomelanin may also contribute to microbial infection persistence. Pyomelanin 
and HGA have the ability to release iron from iron chelates that occur in a mammalian 
host, including ferritin and transferrin, or in the environment, such as ferric hydroxide 
(81). The ability to obtain iron from the environment may be important in bacterial 
persistence during infection since iron is necessary for bacterial growth. Many metabolic 
pathways and cellular functions require iron (88), including the PhhA, Hpd, and HmgA 
enzymes involved in phenylalanine/tyrosine catabolism that have an iron cofactor in the 
active site of the enzyme. 
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Melanin is also known to scavenge superoxide anion produced by macrophages 
(37). Pyomelanin producing B. cenocepacia showed reduced trafficking to RAW 264.7 
lysosomes compared to a non-pigmented strain (36), which suggested that the bacteria 
may be persisting inside the phagocyte. Additionally, in A. fumigatus, transcription of 
tyrosine catabolism genes was induced in response to human neutrophils, which 
suggested that pyomelanin could be involved in immune system escape and fungal 
survival in humans (35). The potential ability of pyomelanogenic microbes to obtain iron 
from host iron chelates, scavenge ROS, reduce trafficking to lysosomes, and induce 
transcription of tyrosine catabolism genes suggest that pyomelanin may play a role in 
bacterial persistence during infection of phagocytes. 
Finally, in a chronic mouse model of infection, pyomelanin producing P. 
aeruginosa exhibited increased persistence compared to the non-pigmented wild type 
strain (56). A mouse model of acute infection showed that pyomelanogenic P. 
aeruginosa had increased persistence compared to non-pigmented wild type (60). It is 
possible that some of the mechanisms described above were used to allow the bacteria 
to persist in the mouse infection models; however, that remains to be tested since the 
mechanism for bacterial persistence was not identified in the mouse studies. In L. 
pneumophila, however, pyomelanin was not involved in intracellular survival of bacteria 
in the amoeba host Hartmannella vermiformis (66), which indicates that pyomelanin 
production is not always involved in infection persistence. These differences in bacterial 
persistence in host organisms could be due to the differences in mammalian and 
amoeba hosts. 
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Several studies, however, have shown that pyomelanin can have a variable 
effect on virulence. In a Caenorhabditis elegans virulence assay, pyomelanogenic P. 
aeruginosa was more virulent than non-pigmented wild type (60). In B. anthracis, 
pyomelanin production did not affect expression of virulence genes (41), which 
demonstrates the potential for a pyomelanin producer to exhibit normal virulence traits. 
Tyrosine degradation genes were upregulated in a mouse infection model, but 
pyomelanin did not appear to have a role in pathogenicity or virulence in A. fumigatus 
(35). Decreased virulence (approximately 2.7 fold) was seen for a V. campbellii 
pyomelanin producer with an in-frame deletion in hmgA in a shrimp virulence model, as 
well as downregulated expression of quorum sensing and bioluminescence genes (63). 
Additionally, decreased virulence by a P. aeruginosa pyomelanin producer was 
observed in an acute mouse model of infection (56). Overall, pyomelanin may have 
some impact on virulence during bacterial and fungal infections, but the studies 
presented above demonstrate that this impact could be microbial species or 
experimental assay dependent. 
Infection persistence and virulence are different but related phenomena in 
microbes. Persistence can be defined as the ability of the microbe to survive longer in a 
host organism than another microbe. It can also mean that the microbe has higher 
numbers of cells than another microbe in a host over a specific time frame. Virulence is 
related to the ability of the microbe to infect a host organism, since a microbe can 
produce virulence factors to increase its ability to cause infection. Virulence can also be 
implicated in microbial killing of the host because a more virulent microbe may cause 
higher mortality of a host than a less virulent microbe. Additionally, in P. aeruginosa, 
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virulence may actually decrease as an infection switches from acute to chronic (89). 
This ability to downregulate virulence demonstrates that there is interplay between 
virulence and persistence in microbial infections, and that there may be advantages to 
persistence over virulence or vice versa, depending on the situation. 
 
1.6 Anti-virulence treatment and NTBC 
 
Bacteria are becoming more resistant to antimicrobial agents such as antibiotics, 
which is a significant problem as most bacterial infections are treated with antibiotics. 
Additionally, very few new antibiotics have been developed in recent years. As an 
alternative to treating infections with antibiotics, anti-virulence therapies that target 
microbial virulence factors are being investigated. Anti-virulence therapy targets 
mechanisms that are beneficial for pathogen interactions with the host, instead of 
targeting functions that are necessary for basic metabolism, which should increase the 
specificity of the therapy for pathogens over the normal flora in the host (90). Good 
targets for anti-virulence therapy include mechanisms involved in bacterial adhesion to 
cells and colonization, secretion of cell surface proteins, regulatory bacterial functions 
such as quorum sensing, cell wall components such as LPS, and pigments (19, 90). 
When selecting a virulence factor for anti-virulence therapy, it is ideal if the target is 
conserved in many species (90) so there is potential for broad application of the 
therapy. 
Microbial pigments can contribute to disease pathogenesis, due to the fact that 
pigments can interfere with host immune clearance and can have proinflammatory or 
cytotoxic properties (91). This can confer a survival advantage for the bacteria when 
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they are in the host. This makes pigments, such as pyomelanin, good targets for anti-
virulence therapy. Since pyomelanin is conserved in a variety of bacterial and fungal 
pathogens there is potential for broad application of an anti-virulence therapy targeting 
that pigment. Additionally, pyomelanin production and a functional 
phenylalanine/tyrosine catabolism pathway are not essential in bacteria, as indicated by 
unimpaired growth of pathway mutants. This makes it less likely for resistance to 
develop to an anti-virulence therapy targeting pyomelanin. Recently, pyomelanin 
production in L. pneumophila was inhibited by a compound that targeted phenylalanine 
hydroxylase (92). Another recent study showed that pyomelanin production in P. 
aeruginosa could be inhibited by 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC) treatment, which targets Hpd, and this pigment inhibition led 
to increased sensitivity to oxidative stress (58). These results demonstrate that there is 
interest in investigating different compounds that inhibit pyomelanin production. 
NTBC was originally developed as an herbicide and binds to Hpd irreversibly at 
its active site, which contains an iron center (93). The active form of Hpd contains a 
ferrous center in the C-terminal domain, and binding of NTBC prevents oxidation of the 
active site (51), thereby inhibiting Hpd function. NTBC has been developed as a 
treatment for type I tyrosinemia (94). Type I tyrosinemia is caused by the lack of 
fumarylacetoacetase (FahA) in the tyrosine catabolism pathway, which causes the 
accumulation of toxic metabolites such as fumarylacetoacetate, leading to cirrhosis and 
cancer of the liver (95). NTBC inhibition of Hpd activity prevents the accumulation of 
toxic metabolites and progression of disease in type I tyrosinemia (94). NTBC treatment 
will also inhibit the formation of HGA, thereby preventing pyomelanin production.  
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Treatment of pyomelanin producing bacteria with NTBC is a novel application for 
an already existing drug that has received FDA approval for treatment of type I 
tyrosinemia in humans (51). Pyomelanin producing bacteria become more sensitive to 
oxidative stress if pigment production is reduced or abolished, which can be achieved 
through NTBC treatment (58). Increased sensitivity to oxidative stress via reduced 
pigmentation is anticipated to increase immune cell mediated killing of bacteria and 
thereby result in increased clearing of infections by the host immune system. Therefore, 
bacterial or fungal infections by pyomelanogenic organisms may exhibit reduced 
persistence after treatment with NTBC, demonstrating the potential for NTBC as an anti-
virulence therapy. 
 
1.7 Concluding remarks 
 
Pyomelanin production in bacteria and fungi is caused by a defect in 
phenylalanine/tyrosine catabolism. This pathway is non-essential in microbes, as 
demonstrated by unimpaired growth of pathway mutants, but it does allow microbes to 
use phenylalanine and tyrosine as energy sources. One of the most common defects 
resulting in pyomelanin production is a loss of HmgA function. Pyomelanin production is 
regulated by global and operon specific regulators that can repress or activate gene 
transcription. Importantly, pyomelanin has several functions that allow microbes to 
survive in different environments, including resistance to oxidative and UV stress, and 
iron reduction and acquisition. The effects of pyomelanin on antibiotic resistance, 
infection persistence, and virulence have shown variability depending on the microbe 
tested and experimental assay conditions. 
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Since pyomelanin has functions that may contribute to pathogenesis and is 
conserved in several pathogenic bacteria and fungi, we investigated NTBC, which is a 
known inhibitor of the tyrosine catabolism pathway, as a potential anti-virulence therapy 
for P. aeruginosa infections. In our studies, we examined mechanisms of pyomelanin 
production in clinical isolates of P. aeruginosa from both acute and chronic infections. 
We also determined the inhibitory effect of NTBC on pyomelanin production and 
subsequent sensitivity to oxidative stress and aminoglycoside antibiotics. Additionally, 
we determined mechanisms for inherent NTBC resistance in clinical isolates of P. 
aeruginosa. Finally, we performed infection assays of the RAW 264.7 murine 
macrophage-like cell line by pyomelanogenic and non-pyomelanogenic strains of P. 
aeruginosa to determine the effects of pyomelanin on bacterial survival during infection. 
Our experiments show that NTBC has potential as an anti-virulence therapy, but 
additional studies must be performed. 
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2.1 Introduction 
Pseudomonas aeruginosa is an environmental bacterium that is capable of 
causing both acute and chronic infections in compromised patients. This organism is 
extremely adaptable, has a high level of intrinsic antibiotic resistance, a wide range of 
virulence factors, and the ability to form biofilms (reviewed in (1)). Antibiotics are an 
essential part of treating P. aeruginosa infections, but the inherent resistance combined 
with emerging resistance due to selective pressure limits the therapeutic options 
available. As a new strategy to combat infectious disease, the specific inhibition of 
virulence factors has been proposed as an alternate treatment mechanism (2). By 
attenuating bacterial virulence without targeting essential bacterial pathways, it may be 
possible to aid in the clearing of infections while minimizing selective pressures that 
perpetuate resistance. 
Pyomelanin, a dark brown/black pigment is a potential target for anti-virulence 
compounds. Pyomelanin production has been reported in P. aeruginosa isolates from 
urinary tract infections and chronically infected cystic fibrosis (CF) patients (3, 4). 
Pyomelanin is one of many forms of melanin that is produced by a wide variety of 
organisms. Production of pyomelanin is reported to provide a survival advantage, 
scavenge free radicals, bind various drugs, give resistance to light and reactive oxygen 
species, and is involved in iron reduction and acquisition, and extracellular electron 
transfer (4-9). A number of environmental and pathogenic bacteria have been reported 
to produce this pigment (3, 8, 10-14). In Shewanella oneidensis and S. algae, 
pyomelanin plays a role in biogeochemical cycling of metals, as pigment production 
enhances hydrous ferric oxide reduction and electron transfer (15-17). In Legionella 
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pneumophilia, pigment production may contribute to pathogenesis as pyomelanin 
mediates ferric reduction from ferritin and transferrin (8). Non-pyomelanogenic strains of 
Burkholderia cepacia are more sensitive to externally generated oxidative stress and 
show reduced survival in phagocytic cells (11). In P. aeruginosa pyomelanin production 
results in increased persistence and virulence in mouse infection models (3). 
Pyomelanin is a negatively charged extracellular pigment of high molecular 
weight, derived from the tyrosine catabolism pathway (6, 18, 19). 4-
hydroxyphenylpyruvate is converted to homogentisate (HGA) by 4-
hydroxyphenylpyruvate dioxygenase (Hpd) (Figure 2.1). HGA is then converted to 4-
maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). A loss of HmgA activity 
leads to the accumulation of HGA, which is secreted via the ABC transporter 
HatABCDE. Defects in either the ATP-binding cassette or the permease components of 
this transporter result in reduced pyomelanin production (4). Once secreted from the 
cell, HGA auto-oxidizes and self-polymerizes to form pyomelanin. Both point mutations 
in hmgA and chromosomal deletions have been reported in clinical P. aeruginosa 
isolates producing pyomelanin (3, 10). 
Hpd activity is essential for the synthesis of HGA, and ostensibly irreversible 
binding with 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione (NTBC) inhibits 
Hpd activity of Streptomyces avermitilis in vitro (20). Although it was originally 
developed as a herbicide, NTBC is a FDA approved treatment for type I tyrosinemia 
(21). Type I tyrosinemia is the result of a defect in the tyrosine catabolism pathway, 
which causes the accumulation of toxic metabolites such as fumarylacetoacetate, 
leading to cirrhosis and cancer of the liver (22). Binding of NTBC to Hpd prevents the 
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Figure 2.1. Tyrosine catabolism pathway of Pseudomonas aeruginosa. Inactivation of HmgA results in 
the secretion of HGA, which auto-oxidizes and self-polymerizes to form pyomelanin. NTBC inhibits 
HGA production and pyomelanin formation through interactions with Hpd. 
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accumulation of toxic metabolites and disease progression (21). We report here on 
NTBC treatment of pyomelanogenic strains of P. aeruginosa, the resulting reduction in 
pyomelanin production, and the corresponding increase in sensitivity to oxidative stress. 
 
2.2 Materials and Methods 
2.2.1 Bacterial strains and growth conditions 
 
Laboratory strains of P. aeruginosa PAO1 (obtained from Carrie Harwood, 
University of Washington), transposon mutants hpd::tn (PW2577) and hmgA::tn 
(PW4489) and the clinical isolate PA1111 (obtained from Dara Frank, MCW) were 
grown at 37°C in LB supplemented with tetracycline (60 µg/ml) and gentamicin (50 
µg/ml) as appropriate. The transposon mutants were obtained from the University of 
Washington transposon mutant collection (23). Escherichia coli DH5α (NEB) was used 
as a host for recombinant plasmids, and was grown in LB with gentamicin (10 µg/ml) as 
appropriate. 
 
2.2.2 Chemicals 
 
NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione), H2O2, and 
tobramycin were purchased from Sigma-Aldrich. Gentamicin and kanamycin were 
purchased from Gold Bio and Fisher Scientific, respectively. 
 
2.2.3 HmgA overexpression 
 
hmgA (PA2009) was amplified from the PAO1 genome using primers hmgAfor (5’ 
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GGTCTAGAATGAACCTCGACTCCACTGC 3’) and hmgArev (5’ 
CCGAGCTCTTATCTCCGTTGCGGGTTG 3’) and cloned into the XbaI and SacI sites of 
pJN105 (24). The PCR product was sequenced to ensure no mutations were 
introduced. The resulting plasmids were transformed into P. aeruginosa strains. 
Following confirmation of transformation, HmgA expression was induced with arabinose 
during overnight growth in LB supplemented with gentamicin. 
 
2.2.4 RT-PCR 
 
Strains were grown overnight until pigment production occurred in pyomelanin 
producers. RNA was isolated from 5x108 cells using RNeasy Mini Kit (Qiagen) and 
digested with DNaseI (Promega). RT-PCR was performed using OneStep RT-PCR Kit 
(Qiagen) with equal concentrations of RNA for all strains tested. Primers were designed 
to amplify 202 base pairs at the 5’ end of hpd, beginning with the start codon. The 
following primers were used: hpD-RT-F (5’ ATGAACGCCGTGCCAAGATCG 3’) and 
hpD-RT-R (5’ CGTTGAGCACGATGTTGATATC 3’). Primers used for the amplification 
of 200 base pairs of 16S rRNA are as follows: 16S-RT-PCR-F (5’ 
GACTCCTACGGGAGGCAGC 3’) and 16S-RT-PCR-R (5’ 
GTATTACCGCGGCTGCTGGC 3’). Relative amounts of RT-PCR products were 
estimated using ImageJ software. 
 
2.2.5 Southern Hybridization 
 
Chromosomal DNA was isolated from laboratory and clinical isolates of 
Pseudomonas aeruginosa, digested with SalI, electrophoresed, and transferred to 
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positively charged nylon membranes by a downward capillary transfer method (25). A 
digoxigenin-labeled probe was generated through amplification of hmgA by PCR and 
the incorporation of digoxigenin-UTP by random priming as recommended by the 
manufacturer (Roche). Southern hybridizations were performed as previously described 
(26). 
 
2.2.6 Growth Curves 
 
Overnight cultures were grown in LB + 300 µM NTBC or LB with the 
corresponding amount of DMSO. The overnight cultures were diluted to OD600 0.05 in 
LB + 300 µM NTBC or LB + DMSO, and the optical density was measured every hour. 
Each sample was pelleted and resuspended in LB prior to the optical density reading to 
ensure the results were not influenced by the presence of pyomelanin. 
 
2.2.7 Oxidative stress assay 
 
Overnight cultures were grown with NTBC (300 µM) or with a corresponding 
volume of DMSO as a control. Optical densities (OD600) were measured using washed 
cells, and cultures were diluted to equivalent OD600 values (~2.5). Ten-fold serial 
dilutions were made in PBS containing either 300 µM NTBC or DMSO as appropriate. 5 
µL of each serial dilution was spotted onto LB plates containing the indicated 
concentration of H2O2. Laboratory strains were incubated for 24 h and PA1111 was 
incubated for 45 h at 37°C. 
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2.2.8 Determination of MICs 
 
Minimal inhibitory concentrations (MICs) were determined by two-fold serial 
microtiter broth dilution (27), using an inoculum of 2.75 x 105 CFU/ml. Inoculum 
concentration was determined using washed cells to ensure that pyomelanin production 
did not affect OD600 readings. NTBC was included in the appropriate wells at a final 
concentration of 300 µM. MICs were recorded as the lowest concentration of antibiotic 
inhibiting growth following 24 h of incubation at 37°C. 
 
2.3 Results and Discussion 
2.3.1 Pyomelanin production by a clinical isolate of P. aeruginosa. 
PA1111, a pyomelanogenic clinical isolate from an acute infection was obtained 
from Dara Frank (Medical College of Wisconsin). This strain lacked type III secretion 
proteins but was cytotoxic in a tissue culture assay (28). To determine the cause of 
pyomelanin production in this isolate, HmgA (PA2009) from PAO1 was expressed from 
pJN105 (24). Following induction with 0.05% and 0.1% arabinose, pyomelanin 
production was eliminated in hmgA::tn and PA1111 respectively (Figure 2.2A). P. 
aeruginosa hmgA::tn functions as a positive control for pyomelanin production as hmgA 
is interrupted with the ISphoA/hah transposon (23). P. aeruginosa PAO1 and hpd::tn 
(isogenic to hmgA::tn) were included as negative controls; neither strain produces 
pyomelanin. 
Since increased amounts of arabinose were required to eliminate pyomelanin 
production in PA1111 relative to hmgA::tn (compare 0.05 to 0.1%), we assayed hpd 
transcript levels through RT-PCR (Figure 2.2B). Quantification of the relative levels 
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Figure 2.2. HmgA expression alleviates pyomelanin production in lab and clinical isolates in a dose 
dependent manner. A) The indicated P. aeruginosa strains containing either hmgA-pJN105 (+) or 
pJN105 (-) were incubated overnight in LB + gentamicin (50 µg/ml) with the indicated concentrations 
of arabinose. B) RT-PCR amplification of hpd transcript in PAO1, hmgA::tn, and PA1111. C) RT-PCR 
amplification of 16S rRNA from PAO1, hmgA::tn and PA1111. 
A. 
B. 
C. 
PAO1 hmgA::tn PA1111 No RT 
PAO1 
hpd::tn 
hmgA::tn 
PA1111 
% arabinose           0               0.05              0.1 
hmgA       -       +          -       +         -        + 
	 50 
revealed that in both PAO1 and PA1111 hpd transcript was approximately 10% more 
abundant than in hmgA::tn. It is unlikely that this subtle increase in hpd transcript levels 
is responsible for the residual pyomelanin production in PA1111 at low levels of 
induction (0.05% arabinose). This suggests that the clinical isolate may have altered 
translation or post-translational modification resulting in increased expression or activity 
of Hpd. 
The ability to abolish pyomelanin production in PA1111 through expression of 
wild type HmgA suggested that either a chromosomal deletion or inactivation of the 
hmgA gene occurred, both of which have been reported in clinical isolates of P. 
aeruginosa (3, 10). A third reported cause of pyomelanin production is imbalanced 
enzyme expression within the L-tyrosine catabolism pathway. In Vibrio cholerae (ATCC 
14035), homogentisate dioxygenase and the downstream enzymes are expressed at 
lower levels than hydroxyphenylpyruvate dioxygenase, leading to an accumulation of 
HGA and pyomelanin production (29). To determine the genetic cause of pyomelanin 
production in PA1111, we attempted to PCR amplify and sequence hmgA. Despite 
repeated attempts, we were unable to amplify hmgA via colony PCR. To verify these 
results, Southern hybridization was performed with DIG-labeled hmgA as a probe. No 
hybridization was detected between the hmgA probe and the PA1111 genome (Figure 
2.3). This, combined with our ability to complement the pyomelanin phenotype via 
induction of hmgA expression, suggests that a chromosomal deletion has occurred.
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Figure 2.3. PA1111 has a chromosomal deletion of hmgA. A) Schematic for predicted band sizes with 
SalI digestion of genomic DNA from PAO1, hpd::tn, and hmgA::tn. Blue, chromosomal DNA upstream 
and downstream from hmgA; red, hmgA; green, phoA transposon (tn) in hmgA. B) Southern blot 
hybridization of DIG-hmgA probe to SalI digested DNA from PAO1, hmgA::tn, PA1111, and hpd::tn. 
Bands at the predicted sizes were seen for PAO1, hmgA::tn, and hpd::tn. PA1111 showed no 
hybridization with DIG-hmgA, indicating that a chromosomal deletion of hmgA occurred. kbp, kilo base 
pairs. 
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2.3.2 NTBC inhibits pyomelanin production in P. aeruginosa without disrupting 
growth. 
NTBC is known to bind Hpd (4-hydroxyphenylpyruvate dioxygenase) and inhibit 
the conversion of 4-hydroxyphenylpyruvate to homogentisate (20). We, therefore, 
assayed NTBC treatment for disruption of pyomelanin production in P. aeruginosa. The 
two pyomelanin producing strains (hmgA::tn and PA1111) were grown overnight with 
increasing amounts of NTBC. Following overnight growth, inhibition of pyomelanin 
production was determined visually (Figure 2.4A). NTBC (300 µM) inhibited pyomelanin 
production in hmgA::tn, while PA1111 required higher concentrations of NTBC to inhibit 
pyomelanin production (900 µM). Sequencing of hpdPA1111 revealed two silent mutations 
upon comparison with hpdPAO1 (PA0865), demonstrating that mutations within Hpd were 
not responsible for the residual PA1111 pyomelanin production in the presence of 300 
µM NTBC. To ensure that NTBC did not alter the growth of P. aeruginosa, we measured 
the optical densities of cultures grown in the presence and absence of NTBC. The 
laboratory strains and PA1111 grew at the same rate in the presence or absence of 300 
µM NTBC (Figure 2.4B), indicating that the reduction in pigmentation was not due to 
altered growth rates. 
 
2.3.3 NTBC treatment of pyomelanogenic strains does not alter aminoglycoside 
MICs. 
It has been reported that melanin has the ability to non-specifically bind a number 
of diverse compounds. Isotherm analysis indicated that gentamicin had a high level of 
binding to synthetic melanin through a series of diverse interactions (30). Melanin-
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Figure 2.4. NTBC treatment inhibits pyomelanin production without affecting growth. A) Pyomelanin 
production by P. aeruginosa with and without NTBC treatment. Laboratory and clinical strains were 
grown overnight with the indicated concentrations of NTBC. B) Growth curves of laboratory and 
clinical strains of P. aeruginosa with and without 300 µM NTBC treatment. Strains grown without 
NTBC are indicated with closed symbols, while those grown with NTBC are indicated with open 
symbols. Wild type PAO1 (diamonds), hpd::tn (triangles), hmgA::tn (squares), PA1111 (circles). The 
growth curves are compiled from three independent experiments, with error bars indicating standard 
error of the mean. 
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tobramycin interactions have resulted in a decrease of antibiotic activity of 80% under 
certain conditions (31). Aminoglycosides are positively charged at physiological pH, 
which may contribute to the interactions with negatively charged melanin (6). 
Furthermore, a significant correlation was seen between pyomelanin production in 
Stenotrophomonas maltophilia and resistance to specific antibiotics (14). We therefore 
assayed both pyomelanin producing and non-producing strains (with and without NTBC 
treatment) to determine the minimal inhibitory concentrations (MICs) of 
aminoglycosides. 
Minimal inhibitory concentrations were determined by two-fold serial microtiter 
broth dilution (27). Our results indicated that, under these conditions, the pyomelanin 
producing strains (hmgA::tn and PA1111) did not show significantly higher 
aminoglycoside MICs than the non-pyomelanin producing strains (PAO1 and hpd::tn, 
Table 2.1). While treatment of the pyomelanin producing strains with NTBC did inhibit 
pyomelanin production, the MICs remained unchanged. These data indicated that 
neither pyomelanin production nor NTBC treatment affect the aminoglycoside MICs for 
P. aeruginosa. This is in agreement with an earlier study wherein MICs were unaltered 
by pyomelanin production (3), and provides further clarity to the discussion within the 
literature regarding pyomelanin production and antibiotic resistance. Early studies of 
pyomelanin production reported that pyomelanogenic P. aeruginosa isolates were more 
sensitive to antibiotics when compared to non-pyomelanogenic strains (32). In contrast, 
when Staphylococcus aureus was incubated in supernatant from pyomelanogenic P. 
aeruginosa, the MIC values remained unchanged (33). When considering the results of 
these studies it is critical consider the sources of the melanin; the isotherm analysis was 
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Table 2.1. Aminoglycoside MICs (µg/ml) of laboratory and clinical isolates of P. aeruginosa. 
Three independent colonies were tested in triplicate for each strain. 
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conducted with eumelanin (or synthetic melanin) generated from 3,4-
dihydroxyphenylalanine (DOPA), not pyomelanin generated from homogentisate (6). It 
is possible that the discrepancy between our results and the isotherm studies is due to 
differences in melanin structures (G. Moran, personal communication). While the S. 
maltophilia studies did correlate pyomelanin production with increased resistance to 
some β-lactam antibiotics and fluoroquinolones, resistance was not detected to either 
gentamicin or trimethoprim/sulfamethoxazole (14). Importantly, a direct causal 
relationship was not tested, and the authors acknowledged that these phenotypes could 
have resulted from independent mutations. 
 
2.3.4 NTBC treatment of pyomelanin producing P. aeruginosa increases 
sensitivity to oxidative stress. 
The antioxidant properties of pyomelanin are proposed to contribute to the 
increased persistence and virulence of pyomelanogenic bacteria in infection models (3, 
11, 12). Since pyomelanogenic strains of Burkholderia cepacia and P. aeruginosa have 
increased resistance to hydrogen peroxide, we examined if NTBC treatment increased 
sensitivity of pyomelanogenic strains of P. aeruginosa to oxidative stress. 
The H2O2 spot plates showed that both pyomelanogenic strains (hmgA::tn and 
PA1111) have increased resistance to hydrogen peroxide relative to the non-
pyomelanogenic strains (PAO1 and hpd::tn) (Figure 2.5). Importantly, NTBC treatment 
of pyomelanogenic strains resulted in increased sensitivity to 0.6 mM H2O2. This 
illustrates the potential use of NTBC as an anti-virulence factor. The change in 
sensitivity to H2O2 was smaller for PA1111 than hmgA::tn, and resulted in an 
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Figure 2.5. NTBC treatment increases H2O2 sensitivity in pyomelanin producing strains. 10-fold serial 
dilutions of the indicated strains were spotted onto LB plates containing the indicated concentrations of 
hydrogen peroxide. 
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approximately 24% reduction in number of PA1111 colony forming units (based on 4 
independent experiments). It is likely that the residual pyomelanin produced in PA1111 
at 300 µM NTBC provides a small level of protection against oxidative stress compared 
to hmgA::tn. As expected, NTBC treatment of either wild type PAO1 or hpd::tn did not 
affect sensitivity to H2O2. 
In this report, we determined that the pyomelanin production in a strain of P. 
aeruginosa PA1111 isolated from an acute infection was likely due to the loss of HmgA 
activity resulting from a chromosomal deletion (28). This phenotype has previously been 
reported for CF isolates and has been shown to decrease clearance/increase 
persistence in mouse models of chronic infection, suggesting that the development of 
pyomelanin production may confer an adaptive advantage (3, 10). Given the antioxidant 
properties of pyomelanin, it is likely that pigment production would provide protection 
from oxidative stress in both chronic and acute infections. 
This study has shown that NTBC treatment inhibited pyomelanin production by P. 
aeruginosa, and in doing so increased the sensitivity of both laboratory and clinical 
isolates to oxidative stress, as is found in the respiratory burst from macrophages and 
monocytes. This suggests that NTBC, as an already FDA-approved compound, has 
potential as an anti-virulence factor that could be used in combination with existing 
antibiotics. Pyomelanin is made by a wide variety of organisms, and has been reported 
in both chronic and acute infections. Given the number of organisms that produce 
pyomelanin, its functions in iron acquisition and as an antioxidant, and the presence of 
pyomelanin in both acute and chronic infections, there are a high number of potential 
applications of NTBC as an anti-virulence factor. 
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Chapter Three 
Resistance to NTBC in the pyomelanogenic Pseudomonas aeruginosa 
clinical isolate DKN343 
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3.1 Introduction 
 
Pyomelanin has several functions that are involved in helping bacteria and fungi 
survive in host organisms or the environment. First, pyomelanin can provide protection 
from oxidative stress and UV light (1-8). Additionally, pyomelanin is involved in electron 
transfer, iron reduction, and iron acquisition (9-12). Studies have also shown that 
pyomelanin may be involved in Pseudomonas aeruginosa infection persistence (2, 13). 
Pyomelanin production in Vibrio campbellii has also been associated with reduced 
virulence (14), which could allow for increased infection persistence. 
Many clinical and environmental bacterial and fungal species have been reported 
to produce pyomelanin, including P. aeruginosa, Burkholderia cepacia complex, Vibrio 
cholerae, Legionella pneumophila, Shewanella algae, Bacillus anthracis, Aeromonas 
media, Acinetobacter baumannii, Sinorhizobium meliloti, Streptomyces coelicolor, 
Alteromonas stellipolaris, Aspergillus fumigatus, Sporothrix sp., and Penicillium 
chrysogenum (4-7, 10, 12, 15-23). In these strains, pyomelanin is either naturally 
produced in the wild type strain or is the result of a mutation or deletion of genes known 
to be involved in pyomelanin production. 
Pyomelanin is a negatively charged, extracellular, reddish-brown pigment derived 
from the tyrosine catabolism pathway when homogentisate (HGA) is secreted from the 
cell via the HatABCDE ABC transport system, auto-oxidized, and self-polymerized 
(Figure 3.1) (2, 24-26). 4-hydroxyphenylpyruvate dioxygenase (Hpd) is required for 
pyomelanin production as it converts 4-hydroxyphenylpyruvate into HGA. Inactivation of 
hpd via deletion or transposon mutagenesis in pyomelanin producers eliminates 
pigment production (5, 12, 26, 27).	During the breakdown of tyrosine, HGA is converted 
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Figure 3.1. Tyrosine catabolism pathway in P. aeruginosa. Pyomelanin is produced via inactivation of 
HmgA, which results in secretion of HGA from the cell and subsequent auto-oxidation and self-
polymerization to form pigment. NTBC binds to Hpd to prevent formation of HGA and pyomelanin 
production. PhhC, aromatic amino acid aminotransferase; Hpd, 4-hydroxyphenylpyruvate 
dioxygenase; HmgA, homogentisate 1,2-dioxygenase; MaiA, maleylacetoacetate isomerase; FahA, 
fumarylacetoacetase; HatABCDE, HatABCDE ABC transporter. 
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into 4-maleylacetoacetate by homogentisate 1,2-dioxygenase (HmgA). Mutations that 
result in loss of HmgA function lead to an accumulation of HGA and consequently 
pyomelanin production (1, 2, 28). A relative reduction in enzyme activity in the latter part 
of the tyrosine catabolism pathway (HmgA, MaiA, and FahA) compared to the upper 
part of the pathway can also lead to pyomelanin production (29). 
Bacteria are becoming more resistant to antibiotics, so investigation into new 
antimicrobial agents is necessary. Anti-virulence therapy targets mechanisms that are 
beneficial for pathogen interactions with the host, instead of targeting functions that are 
necessary for basic metabolism (30). This allows the therapy to have specificity for 
pathogens over the normal flora in the host (30). Since pyomelanin has several 
functions that may be advantageous for bacterial or fungal survival in a host, and has 
been reported to contribute to infection persistence, it is an ideal target for anti-virulence 
therapy. We have previously shown that the Hpd inhibiting compound 2-(2-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) reduces pyomelanin production 
in P. aeruginosa clinical isolates and increases sensitivity to oxidative stress (1). NTBC, 
therefore, shows promise as an anti-virulence treatment. 
P. aeruginosa is a Gram negative bacterium that is able to survive in a variety of 
different ecological environments including soil, water, plants, and animals (31). This 
organism is also an opportunistic pathogen that frequently colonizes the lungs of cystic 
fibrosis (CF) patients, where it causes chronic infections by forming biofilms (32). 
Additionally, it causes acute infections in burn patients (33, 34). P. aeruginosa is 
capable of producing a variety of virulence factors including secreted proteins, toxins, 
and pigments that may help the bacteria survive during infection (35). 
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In our current study, we identified the mechanism of pyomelanin production in the 
clinical P. aeruginosa isolate DKN343. DKN343 was previously reported to have a wild 
type hmgA sequence, and expression of hmgA from a plasmid did not alleviate 
pyomelanin production, which suggested that pyomelanin was produced via a different 
mechanism than inactivation of HmgA (26). We found, however, a mutation in HmgA 
that is predicted to render the enzyme non-functional causing a defect in tyrosine 
catabolism and resulting in pyomelanin production. In addition, we discovered a high 
level of pre-existing resistance to NTBC, which was mediated by the MexAB-OprM 
multi-drug efflux pump. 
 
3.2 Materials and Methods 
 
3.2.1 Strains, plasmids, and growth conditions 
 
Lists of strains and plasmids are found in Tables 3.1 and 3.2, respectively. 
Strains were grown on LB agar or in LB broth supplemented with gentamicin, 
tetracycline, or chloramphenicol where appropriate. Antibiotic concentrations were as 
follows: gentamicin 10 µg ml-1 (E. coli), 50 µg ml-1 (hpd::tn, hmgA::tn, and DKN343 in 
broth media), and 100 µg ml-1 (DKN343 on agar); tetracycline 10 µg ml-1 (E. coli) and 
195 µg ml-1 (DKN343); chloramphenicol 5 µg ml-1. Strains were grown at 37°C unless 
otherwise indicated. 
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Table 3.1. Strains used in this study. 
Strains Description Source 
P. aeruginosa PAO1 P. aeruginosa PAO1 (Iglewski 
strain) 
Carrie Harwood 
P. aeruginosa hpd::tn PW2577, transposon mutant 
with lacZ-tn inserted in hpd, 
TcR, pyomelanin non-producer 
University of 
Washington PAO1 
transposon mutant 
collection 
P. aeruginosa hmgA::tn PW4489, transposon mutant 
with phoA-tn inserted in hmgA, 
TcR, pyomelanin producer 
University of 
Washington PAO1 
transposon mutant 
collection 
P. aeruginosa DKN343 Clinical isolate of P. aeruginosa 
from sputum sample, 
pyomelanin producer 
(26) 
E. coli DH5α fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
New England Biolabs 
E. coli S17-1 TpR SmR recA thi pro hsdR- M+ 
RP4 2-Tc::Mu-Km::Tn7 λpir 
Strain for conjugating plasmids 
(36) 
 
hmgA::tnΔhpd In-frame deletion of hpd in 
hmgA::tn 
This study 
DKN343Δhpd In-frame deletion of hpd in 
DKN343 
This study 
hmgA::tnΔmexA In-frame deletion of mexA in 
hmgA::tn 
This study 
DKN343ΔmexA In-frame deletion of mexA in 
DKN343 
This study 
hmgA::tnΔPA0242 In-frame deletion of PA0242 in 
hmgA::tn 
This study 
DKN343ΔPA0242 In-frame deletion of PA0242 in 
DKN343 
This study 
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Table 3.2. Plasmids used in this study. 
Plasmids Description Source 
pEX18Tc Suicide vector for making deletion 
mutants, TcR 
Carrie Harwood 
pEX19Gm Suicide vector for making deletion 
mutants, GmR 
Carrie Harwood 
Δhpd-pEX18Tc Fusion fragment for hpd deletion 
cloned into pEX18Tc at the BamHI 
and HindIII sites 
This study 
Δhpd-pEX19Gm Fusion fragment for hpd deletion 
cloned into pEX19Gm at the EcoRI 
and HindIII sites, EcoRI site was 
from pEX18Tc 
This study 
ΔmexA-pEX18Tc Fusion fragment for mexA deletion 
cloned into pEX18Tc at the XbaI 
and KpnI sites 
This study 
ΔmexA-pEX19Gm Fusion fragment for mexA deletion 
cloned into pEX19Gm at the XbaI 
and KpnI sites 
This study 
ΔPA0242-pEX18Tc Fusion fragment for PA0242 
deletion cloned into pEX18Tc at the 
SacI and HindIII sites 
This study 
ΔPA0242-pEX19Gm Fusion fragment for PA0242 
deletion cloned into pEX19Gm at 
the SacI and HindIII sites 
This study 
pSB109 Derivative of pJN105 with an 
enhanced ribosome binding site, 6x-
His tag, GmR 
This study 
hmgA-pSB109 hmgA from PAO1 cloned into 
pSB109 at the NdeI and SacI sites 
This study 
hmgAA306T-pSB109 hmgA from PAO1 with point 
mutation for A306T 
This study 
hmgAH330Y-pSB109 hmgA from PAO1 with point 
mutation for H330Y 
This study 
hpd-pSB109 hpd from PAO1 cloned into pSB109 
at the NdeI and SacI sites 
This study 
mexA-pSB109 mexA from PAO1 cloned into 
pSB109 at the NdeI and SacI sites 
This study 
PA0242-pSB109 PA0242 from PAO1 cloned into 
pSB109 at the EcoRI and SacI sites 
This study 
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3.2.2 Generation of deletion mutants 
 
In-frame deletion mutants of hpd, mexA and PA0242 in P. aeruginosa were 
constructed by splicing by overlap extension (SOE) PCR with PAO1 DNA as template. 
Primers are listed in Table 3.3. The in-frame fusions were sequenced to ensure no 
mutations were introduced. The deletion alleles were cloned into pEX19Gm or pEX18Tc 
and transformed into E. coli S17-1 for mating with P. aeruginosa hmgA::tn and DKN343, 
respectively. These constructs were introduced into P. aeruginosa by conjugation, and 
merodiploids were selected on chloramphenicol and tetracycline or gentamicin as 
appropriate and incubated overnight (hmgA::tn) or two days (DKN343) to isolate 
merodiploids. Resolution of the merodiploids was achieved through 10% sucrose 
counter selection. Following screening on tetracycline or gentamicin and sucrose, the 
deletions were confirmed by PCR or Southern blot.  
 
3.2.3 NTBC titrations 
 
NTBC titrations were performed as previously described (37) with gentamicin and 
arabinose supplementation where appropriate. NTBC (Sigma-Aldrich) was dissolved in 
DMSO and stored at -20°C until use. Cultures were incubated for approximately 24 
hours before photos were taken for analysis. 
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Table 3.3. Primers used in this study. 
Primer name Primer Sequence (5’ – 3’)a,b 
Primers for in-frame deletions 
Δhpd-up-For GTAGCGGATCCCGATGCCTGCCACCGGAC 
Δhpd -up-Rev GAGGCTGGCGGCAGCGGGACCGGCCTCCTCGTTGT
TC 
Δhpd -dn-For GAACAACGAGGAGGCCGGTCCCGCTGCCGCCAGCC
TC 
Δhpd -dn-Rev CGCCGAAGCTTGCCGCGGTGAAGCCGAGC 
ΔmexA-up-For CCTCTAGACATCACCGGCAACCTGACCC 
ΔmexA -up-Rev CCCCTTGATCAGCCCTTGCTTCGTTGCATAGCGTTGT
CCTC 
ΔmexA -dn-For GAGGACAACGCTATGCAACGAAGCAAGGGCTGATCA
AGGGG 
ΔmexA -dn-Rev GGGGTACCTACGGGTAGACCACCTTC 
ΔPA0242-up-For CCAAGAGCTCAACCACAGGCGGGTGGTC 
ΔPA0242-up-Rev GACAATTCTCACAGCTTGACACGCTGCATGCTTCGAC
TC 
ΔPA0242-dn-For GAGTCGAAGCATGCAGCGTGTCAAGCTGTGAGAATT
GTC 
ΔPA0242-dn-Rev GTCCAAGCTTCCTGTGGGTCGCCGAGGTG 
Primers for gene sequencing 
hmgA-external forward CGATAAAAATAACGCAGCCAGC 
hmgA-external reverse GGTTTTGCAGGGGAAAGTCG 
hpd-external forward GGCATCTCCCATGTCGTCGGC 
hpd-external reverse GCCGCTGGAACGGAAACGC 
Primers for complementation 
hmgA-for-pSB109 GGCATATGATGAACCTCGACTCCACTGC 
hmgA-rev CCGAGCTCTTATCTCCGTTGCGGGTTG 
hpd-for-pSB109 GGCATATGATGAACGCCGTGGCCAAG 
hpd-rev GGGAGCTCGGATCAGATCACGCCGCG 
mexA-for-pSB109 CCCATATGATGCAACGAACGCCAGCC 
mexA-rev GGGAGCTCTCAGCCCTTGCTGTCGGTTTTC 
PA0242-for-pSB109 GGGAATTCATGCAGCGTTCGATCGCC 
PA02424-rev GGGAGCTCATTCTCACAGCTTGACCC 
Primers for site directed mutagenesis 
hmgA-A306T-for CAGCGTCCCCGGCCTGACCAACATCGACTTCGTG 
hmgA-A306T-rev CACGAAGTCGATGTTGGTCAGGCCGGGGACGCTG 
hmgA-H330Y-for CCGTCCGCCATGGTTCTACCGCAACCTGATGAACG 
hmgA-H330Y-rev CGTTCATCAGGTTGCGGTAGAACCATGGCGGACGG 
aRestriction enzyme sites are underlined. 
bMutagenic codons are in bold.
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3.2.4 Sequencing of hmgA and hpd from DKN343 
 
hmgA and hpd from DKN343 were PCR amplified using the appropriate primers 
(Table 3.3), purified, and sequenced. The sequencing results were compared to P. 
aeruginosa PA14 to identify any mutations. 
 
3.2.5 Complementation studies 
 
Plasmids for complementation were created by amplifying hmgA, hpd, mexA, 
and PA0242 from PAO1 using the appropriate primers (Table 3.3). Gene fragments 
were sequenced and cloned into pSB109. Plasmids were maintained in E. coli DH5α 
and transformed into the appropriate P. aeruginosa strain. Strains containing pSB109 
empty vector were used as controls. Test tubes containing LB and gentamicin were 
inoculated with washed overnight cultures to a concentration of OD600 0.05 (hpd::tn and 
hmgA::tn) or 0.1 (DKN343) and grown to OD600 0.2-0.3 before induction with arabinose 
(0-0.5%) for 1.5 h. Whole cell lysates were separated by SDS-PAGE. The remaining 
cultures were incubated for a total of 24 hours and photos were taken for analysis. 
 
3.2.6 Site directed mutagenesis 
 
Single point mutations of A306T and H330Y in hmgA were generated by site 
directed mutagenesis. PCR was performed with the appropriate mutagenic primers 
(Table 3.3) using the hmgA-pSB109 plasmid as template. The PCR product was 
digested with DpnI (New England Biolabs) and transformed into DH5α cells. The 
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plasmid DNA was sequenced to confirm the introduced mutation was present and 
transformed into hmgA::tn for complementation studies as described above. 
 
3.2.7 SDS-PAGE and Western blots 
 
Whole cell lysates from complementation studies were analyzed by SDS-PAGE 
on 10% gels. Proteins were transferred to PVDF and probed using mouse-α-His 
antibody (1:3000) and sheep-α-mouse horseradish peroxidase antibody (1:10000). 
Signal was detected using SuperSignal West Femto Maximum Sensitivity Substrate and 
a CCD camera with Fotodyne software. 
 
3.2.8 Nitrocefin hydrolysis assay 
 
The nitrocefin assay to determine outer membrane permeability was modified 
from previously described procedures (38, 39). Overnight cultures were diluted 1:60 in 
30 ml LB and incubated for 2 h at 37°C with shaking. Imipenem (0.25 µg ml-1) was 
added to induce β-lactamase expression. Cultures were incubated for an additional 3 h 
before cells were harvested by centrifugation (5000 xg, 10 min). Cell concentration was 
normalized based on OD600, and cell pellets were washed and concentrated in 50 mM 
sodium phosphate buffer (pH 7.2). Aliquots of cells were treated with 0 and 0.1 mM 
EDTA for 5 min. Samples were centrifuged at 15000 xg for 30 min at room temperature 
and β-lactamase containing supernatant was saved. β-lactamase containing 
supernatant was diluted in 50 mM sodium phosphate buffer (pH 7.2) and nitrocefin 
(Calbiochem) was added at a final concentration of 100 µM in a total volume of 1 ml. 
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Nitrocefin hydrolysis was measured spectrophotometrically at 482 nm and β-lactamase 
activity (U/L) was calculated using the extinction coefficient of 17.4 mM-1 cm-1 for 
nitrocefin. The enzyme activity per OD600 of cells was calculated and averaged over five 
biological replicates. Statistical analysis was performed by ANOVA, followed by Tukey 
HSD post-hoc analysis using R (version 3.2.4). 
 
3.2.9 Measurement of pyomelanin production in strains treated with EDTA and 
NTBC 
LB containing 0 and 0.1 mM EDTA with 0 and 50 µM NTBC for hpd::tn and 
hmgA::tn, or 0 and 900 µM NTBC for DKN343, were inoculated to an OD600 0.05 with 
washed overnight cultures. Cultures were grown for approximately 24 h, then cells were 
pelleted by centrifugation (2 min, 16000 xg), supernatants were collected, and the cell 
pellet was suspended in an equivalent volume of LB. OD600 measurements of the 
pyomelanin containing supernatant and the resuspended cells were used to calculate 
the ratio of pyomelanin to cells. This ratio was averaged for three colonies tested in 
triplicate and percent pyomelanin produced relative to the untreated strain was 
calculated. 
 
3.2.10 Photo analysis and image manipulation 
 
All photos were taken on a Canon PowerShot A480 digital camera. Photos were 
cropped in Adobe Photoshop and image resolution was adjusted to 600 pixels/inch. 
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3.3 Results 
 
Previous studies in our laboratory have focused on the ability of NTBC to inhibit 
pyomelanin production in clinical isolates of P. aeruginosa (1). During these studies we 
determined that the clinical isolate DKN343 required increased concentrations of NTBC 
to inhibit pyomelanin production when compared to the pyomelanogenic control 
hmgA::tn (Figure 3.2). DKN343 was isolated from a sputum sample (D. Newman, 
personal communication) and was reported to have wild type PA14 sequence in hmgA 
(26). Pyomelanin production typically results from either point mutations or deletions of 
hmgA, or an imbalance in enzyme activity within the tyrosine catabolism pathway (2, 28, 
29). We therefore investigated the mechanism of pyomelanin production and resistance 
to NTBC in this clinical isolate. 
 
3.3.1 Pyomelanin production in DKN343 results from a loss of function mutation 
in HmgA. 
 To determine the mechanism for pyomelanin production, hmgADKN343 was PCR 
amplified and sequenced, revealing two mutations when compared to PA14 hmgA; in 
the resulting protein the mutated residues were A306T and H330Y (Figure 3.3). These 
mutations suggested to us that, contrary to previous reports, DKN343 may produce 
pyomelanin due to a loss of function mutation in HmgA. Additionally, the H330Y 
mutation occurred in the HmgA iron co-factor binding site, which we hypothesized would 
be required for functional HmgA. We therefore assayed the role of the tyrosine 
catabolism pathway in DKN343 pyomelanin production.
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hpd::tn 
hmgA::tn 
DKN343 
µM NTBC      0       50    100    200     300   600    900 
Figure 3.2. NTBC treatment reduced pigment production in pyomelanogenic P. aeruginosa strains. 
Strains were grown in LB with the indicated concentrations of NTBC. The non-pyomelanogenic control 
hpd::tn showed no pigment change in response to NTBC treatment. The pyomelanin producers 
hmgA::tn and DKN343 showed dose dependent reductions in pigmentation with increasing 
concentrations of NTBC. hmgA::tn was the positive control for pyomelanin production. The clinical 
isolate DKN343 was less responsive to NTBC than the laboratory strain hmgA::tn, as indicated by the 
requirement for higher concentrations of NTBC to reduce pyomelanin production. 
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PA14        MNLDSTALAYQSGFGNEFSSEALPGALPVGQNSPQKAPYGLYAELLSGTAFTMARSEARR 60 
DKN343      MNLDSTALAYQSGFGNEFSSEALPGALPVGQNSPQKAPYGLYAELLSGTAFTMARSEARR 60 
            ************************************************************ 
  
PA14        TWLYRITPSAKHPPFRRLERQIAGAELDAPTPNRLRWDPLALPEQPTDFLDGLLRMAANA 120 
DKN343      TWLYRITPSAKHPPFRRLERQIAGAELDAPTPNRLRWDPLALPEQPTDFLDGLLRMAANA 120 
            ************************************************************ 
  
PA14        PGDKPAGVSIYQYLANRSMERCFYDADGELLLVPQLGRLRLCTELGALQVEPLEIAVIPR 180 
DKN343      PGDKPAGVSIYQYLANRSMERCFYDADGELLLVPQLGRLRLCTELGALQVEPLEIAVIPR 180 
            ************************************************************ 
  
PA14        GMKFRVELLDGEARGYIAENHGAPLRLPDLGPIGSNGLANPRDFLAPVARYEDSRQPLQL 240 
DKN343      GMKFRVELLDGEARGYIAENHGAPLRLPDLGPIGSNGLANPRDFLAPVARYEDSRQPLQL 240 
            ************************************************************ 
  
PA14        VQKYLGELWACELDHSPLDVVAWHGNNVPYKYDLRRFNTIGTVSFDHPDPSIFTVLTSPT 300 
DKN343      VQKYLGELWACELDHSPLDVVAWHGNNVPYKYDLRRFNTIGTVSFDHPDPSIFTVLTSPT 300 
            ************************************************************ 
  
PA14        SVHGLANIDFVIFPPRWMVAENTFRPPWFHRNLMNEFMGLIQGAYDAKAGGFVPGGASLH 360 
DKN343      SVHGLTNIDFVIFPPRWMVAENTFRPPWFYRNLMNEFMGLIQGAYDAKAGGFVPGGASLH 360 
            *****:***********************:****************************** 
  
PA14        SCMSAHGPDAESCDKAIAADLKPHRIDQTMAFMFETSQVLRPSRAALETPALQNDYDACW 420 
DKN343      SCMSAHGPDAESCDKAIAADLKPHRIDQTMAFMFETSQVLRPSRAALETPALQNDYDACW 420 
            ************************************************************ 
  
PA14        ASLVSTFNPQRR 432 
DKN343      ASLVSTFNPQRR 432 
            ************ 
Figure 3.3. Two amino acid changes were identified in the HmgA protein sequence from the clinical 
isolate DKN343 compared to the HmgA sequence from P. aeruginosa PA14. The two amino acid 
changes, A306T and H330Y, are highlighted in red. The H330Y change occurred in the iron cofactor 
binding site of HmgA. Clustal O (1.2.1) multiple sequence alignment of the HmgA protein from PA14 
and DKN343 was used to identify the amino acid changes in DKN343. 
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 Because pyomelanin production requires an accumulation of HGA, we created 
an in-frame deletion of hpd in DKN343, as well as in the pyomelanogenic control 
hmgA::tn. Deletion of hpd resulted in a loss of pyomelanin production in both hmgA::tn 
and DKN343, while complementation studies restored pyomelanin production (Figure 
3.4A). These data indicate that Hpd is required for pyomelanin production in DKN343. 
 In order to determine if pyomelanin production is due to a loss of function 
mutation in HmgADKN343, wild type hmgAPAO1 was expressed from an arabinose 
inducible promoter in DKN343 and the positive control hmgA::tn (Figure 3.4B). Low 
levels of HmgA expression alleviated pyomelanin production in both strains, which 
demonstrated that pigment production results from a defect in HmgADKN343 function. To 
ascertain whether the A306T or the H330Y mutation was responsible for this loss of 
function, site directed mutagenesis was used to introduce each mutation in hmgAPAO1, 
and these constructs were tested for their ability to complement the hmgA::tn strain 
(Figure 3.4B). Expression of HmgAA306T eliminated pigmentation, demonstrating that this 
mutation is still functional. HmgAH330Y did not affect pyomelanin production, which 
indicated that the H330Y mutation is responsible for loss of function in HmgADKN343. 
Western blots indicated similar levels of protein expression with both point mutations, 
thereby eliminating the possibility that HmgAH330Y fails to complement due to protein 
instability. 
 Together, these data clearly indicate that pyomelanin production in DKN343 
occurs in the traditional manner: HGA is produced by Hpd, but a loss of function 
mutation in HmgA prevents the conversion of HGA to 4-maleylacetoacetate. The 
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Figure 3.4. Pyomelanin production in DKN343 occurs through the tyrosine catabolism pathway. A) 
Hpd is required for pyomelanin production in DKN343. Deletion of hpd resulted in loss of pyomelanin 
production in hmgA::tn and DKN343. Complementation of hpd deletion mutants with His-Hpd restored 
pyomelanin production. The level of His-Hpd expression was determined through anti-His western 
blotting. B) Point mutation in HmgA causes pyomelanin production in the clinical isolate DKN343. 
Expression of WT His-HmgA in trans eliminated pyomelanin production in DKN343, which indicated 
that a defect in hmgA is responsible for pyomelanin production in this strain. The H330Y mutation in 
HmgA did not alleviate pyomelanin production in hmgA::tn, but had no effect on protein expression, 
which indicated that the H330 residue is important for HmgA function but not protein levels. The 
A306T mutation in HmgA had no effect on HmgA function, as indicated by the absence of pyomelanin 
production in hmgA::tn. Anti-His western blots for both WT and mutated His-HmgA showed increased 
protein expression with increasing concentrations of arabinose. Strains were grown in LB containing 
gentamicin with the indicated arabinose concentrations to induce His-HmgA expression. In panels A 
and B, hpd::tn was the non-pyomelanogenic control, while hmgA::tn functioned as a positive control 
for pyomelanin production resulting from a defect in the tyrosine catabolism pathway. 
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intracellular HGA is then secreted from DKN343 by the HatABCDE ABC transporter 
where it is auto-oxidized and self-polymerized into pyomelanin. 
 
3.3.2 Resistance to NTBC is mediated through the MexAB-OprM multi-drug efflux 
pump. 
Studies on the NTBC-mediated inhibition of Streptomyces avermitilis 4-
hydroxyphenylpyruvate dioxygenase (HppD) revealed that NTBC binds irreversibly to 
the ferrous metal center in the active site of the enzyme (40). In our previous studies of 
pyomelanogenic P. aeruginosa, NTBC treatment inhibited pyomelanin production in a 
dose dependent manner (1). Early assays on DKN343 revealed 900 µM NTBC only 
partially inhibited pyomelanin production (Figure 3.2). This is a notable increase 
(approximately 12 fold) in the amount of NTBC required compared to the 
pyomelanogenic laboratory strain hmgA::tn, and suggested this clinical isolate 
possessed pre-existing resistance to NTBC. Because NTBC has been proposed as an 
anti-virulence agent, it was necessary to ascertain the mechanism of resistance. We 
investigated several ways Hpd would remain unaffected by NTBC, including mutations 
in Hpd, possible sequestration of NBTC by the potential Hpd homolog PA0242, the 
influence of outer membrane impermeability, and the effect of the constitutively active 
multi-drug efflux pump MexAB-OprM. 
A common mechanism of antibiotic resistance in bacteria is through target 
alterations. We therefore investigated the possibility that the high level of resistance in 
DKN343 was due to the inability of NTBC to inactivate HpdDKN343. Analysis of the 
hpdDKN343 sequence failed to identify any mutations relative to the PA14 hpd sequence, 
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suggesting that NTBC should be able to bind and inactivate HpdDKN343. We also 
examined the P. aeruginosa PAO1 genome for proteins with homology to the active site 
of Hpd with the possibility that these proteins are binding and sequestering NTBC, 
thereby increasing the concentration needed for inhibition of pyomelanin production. 
Using a BlastP alignment, we identified the hypothetical protein PA0242, wherein the C-
terminal region of the protein has homology to Hpd, including conservation surrounding 
the iron co-factor binding sites where NTBC binds (Figure 3.5A). Deletion of PA0242 in 
hmgA::tn and DKN343 did not increase sensitivity of these strains to NTBC (Figure 
3.5B), suggesting that PA0242 does not contribute to resistance by sequestering NTBC 
away from the target enzyme Hpd. These results demonstrate that mutations in Hpd 
and the presence of the potential Hpd homolog PA0242 do not have an impact on 
NTBC resistance in DKN343. 
P. aeruginosa is known to have low outer membrane permeability, which can 
contribute to antimicrobial resistance (31). We therefore investigated the effects of 
increasing outer membrane permeability on NTBC sensitivity. Similar increases in outer 
membrane permeability were seen in hpd::tn, hmgA::tn, and DKN343 following 
treatment with 0.1 mM EDTA when compared to the untreated strain. Nitrocefin 
hydrolysis by β-lactamase released from the periplasm was used as an indicator of 
outer membrane permeability (Figure 3.6A). Treatment of bacterial strains with sub-
inhibitory concentrations of NTBC (50 µM for hmgA::tn and hpd::tn and 900 µM for 
DKN343) and 0.1 mM EDTA revealed that increasing outer membrane permeability did 
not increase sensitivity to NTBC (Figure 3.6B). In DKN343, the percent of pyomelanin 
produced in the NTBC treated strains relative to an untreated strain was very similar 
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Figure 3.5. PA0242 is not involved in NTBC resistance. A) Clustal O (1.2.0) sequence alignment of P. 
aeruginosa PAO1 Hpd and PA0242 amino acid sequence. Hpd has sequence similarity to the C-
terminal portion of the hypothetical protein PA0242. The iron cofactor binding sites for Hpd (H168, 
H246, and E325) and PA0242 (H443, H521, and E599) are highlighted in red. B) Deletion of PA0242 
had no effect on NTBC sensitivity in the pyomelanin producers hmgA::tn and DKN343. hpd::tn was the 
non-pyomelanogenic control, while hmgA::tn was a positive control for pyomelanin production. 
Cultures were grown with the indicated concentrations of NTBC. 
Hpd         -------------------------------------MNAVAK-IEQHNPIGTDGFEFVE 22 
PA0242      FNDGFRAAPTRANAVDGLRSLLYLEEKTREHLQRQTPHVAVDELFAPPPASLCDGIEFLE 300 
                                                   ** : :        **:**:* 
  
Hpd         FTAPDAKGIEQLRQLFNMMGFTETAKHRSKEVFLFQQNDINIVLNGSPTGHVHEFALKHG 82 
PA0242      FAVDETLGA-RLGQWLQRLGFARAGEHRSKNVSLLRQGDINLVLNAEPYSFAHGFFEAHG 359 
            *:. :: *  :* * :: :**:.:.:****:* *::* ***:***..* ...* *   ** 
  
Hpd         PSACAMAFRVKNASQAAAYAESQGAKLVGSHANFGELNIPSLEGIGGSLLYLVDRYG-DR 141 
PA0242      PSLCATALCVRDAGQALERARAYGGQPYRGLLGPNEREIPAVRALDGSLLYLVERHTEGR 419 
            ** ** *: *::*.**   *.: *.:   .     * :**::..: *******:*:   * 
  
Hpd         SIYDVDFEFIEGRSANDNSVGLTYIDHLTHNVKRGQMDVWSGFYERIANFREIRYFDIEG 201 
PA0242      SIYDSDFVTN---DADTSGLGLRRVDHVALALPAEGLDSWVLFYKSLFDFGADDEVVLPD 476 
            **** **      .*: ..:**  :**::  :    :* *  **: : :*     . :   
  
Hpd         KLTGLFSRAMTAPCGKIRIPINESADDTSQIEEFIREYHGEGIQHIALTTDDIYATVRKL 261 
PA0242      PYGLVTSRAVRSPCGSVRLPLNISEDRNTAIARSLSSYRGSGVHHIAFDCADIFAAVAQA 536 
                : ***: :***.:*:*:* * * .: * . : .*:*.*::***:   **:*:* :  
  
Hpd         RDNGVKFMSTPDTYYEKVDTRVAGHGEPLEQLRELNLLIDGAPGDDGILLQIFTDTVIGP 321 
PA0242      KEAGVALLEIPLNYYDDLAARFDFDDEFLSELAYYNVLYDRD-AQGGELFHVFTEPFEER 595 
            :: ** ::. * .**:.: :*.  . * *.:*   *:* *   .: * *:::**: .    
  
Hpd         IFFEIIQRK-GNQGFGEGNFKALFESIEEDQIRRGVI---- 357 
PA0242      FFFEILQRRHGYAGYGAANVPVRLAAM--AQARRGVRRVKL 634 
            :****:**: *  *:* .*. . : ::   * ****      
A. 
µM NTBC       0       50    100    200     300   600    900 
hpd::tn (V) 
hmgA::tn (V) 
hmgA::tnΔPA0242 (V) 
DKN343 (V) 
DKN343ΔPA0242 (V) 
B. 
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Figure 3.6. An increase in outer membrane permeability does not result in increased sensitivity to 
NTBC in P. aeruginosa. A) EDTA treatment of cells increased outer membrane permeability, as 
measured by extracellular β-lactamase activity via nitrocefin hydrolysis. β-lactamase activity 
(U/L/OD600) for each untreated parent strain (0 mM EDTA) was set to 100% and percent β-lactamase 
activity was calculated following 0.1 mM EDTA treatment. Five biological replicates were tested. 
ANOVA followed by Tukey HSD post-hoc analysis: **, p<0.01; ***, p<0.001. B) hpd::tn, hmgA::tn, and 
DKN343 were treated with 0 or 0.1 mM EDTA and sub-inhibitory concentrations (0, 50, or 900 µM) of 
NTBC, as indicated, for 24 hours. hpd::tn was the non-pyomelanogenic control strain and hmgA::tn 
was the positive control for pyomelanin production. The percent pyomelanin produced was calculated 
from the supernatant:culture ratio (OD600) and the untreated strains were set to 100%. Three biological 
replicates were tested in triplicate.  
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with and without EDTA treatment, but in hmgA::tn, however, the percent of pyomelanin 
produced in the NTBC treated strains was actually higher in the EDTA treated strain. 
These results demonstrate that low outer membrane permeability in DKN343 does not 
contribute to the heightened NTBC resistance. 
Multi-drug efflux pumps contribute to antimicrobial resistance by extruding a 
broad range of compounds from the bacterial cell (41). We therefore tested the 
contribution of the constitutively active multi-drug efflux pump MexAB-OprM to NTBC 
resistance by making in-frame deletions of mexA, which codes for the membrane fusion 
protein of the pump. Increased sensitivity to NTBC was observed in the hmgA::tn and 
DKN343 mexA mutants, as indicated by reduced levels of NTBC (50 µM for hmgA::tn 
and 100 µM for DKN343) required to inhibit pyomelanin production, and restoration of 
pigmentation by complementation (Figure 3.7). These results indicate that the MexAB-
OprM multi-drug efflux pump mediates resistance to NTBC. 
 
3.4 Discussion 
 
 This study determined the mechanism of pyomelanin production in the clinical P. 
aeruginosa sputum isolate DKN343, as well as the mechanism of resistance to NTBC. 
Pyomelanin was produced through the tyrosine catabolism pathway, not an alternate 
mechanism as was previously suggested for DKN343 (26). A singe amino acid change 
in HmgA was identified, and is expected to result in a loss of enzyme function. In 
addition, we observed that DKN343 was more resistant to NTBC than the laboratory 
strain hmgA::tn (Figure 3.2), and therefore investigated the mechanism of resistance. 
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hpd::tn (V) 
hmgA::tn (V) 
hmgA::tnΔmexA (V) 
hmgA::tnΔmexA (His-MexA) 
DKN343 (V) 
DKN343ΔmexA (V) 
DKN343ΔmexA (His-MexA) 
µM NTBC       0       50    100    200     300    600   900 
Figure 3.7. Resistance to NTBC is mediated through the MexAB-OprM multi-drug efflux pump. 
Deletion of mexA in hmgA::tn and DKN343 increased sensitivity to NTBC as indicated by reduced 
levels of pyomelanin. Strains complemented with His-MexA showed restoration of pyomelanin 
production in the presence of NTBC. hpd::tn (V) was the pyomelanin non-producer control. Cultures 
were grown in LB with gentamicin and 0.05% arabinose with the indicated concentrations of NTBC. 
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After testing several possible mechanisms for NTBC resistance, we determined that the 
multi-drug efflux pump MexAB-OprM was responsible. 
The determination that a mutation in HmgA resulted in pyomelanin production is 
not unexpected. Previous studies in several bacteria have also identified mutations in 
hmgA as a cause for pyomelanin production. Analysis of several naturally 
pyomelanogenic strains of V. cholerae revealed that they contained either a 15 or 10 
base pair (bp) deletion mutation in homogentisate oxygenase, and the 15 bp deletion 
was conserved in six O139 strains that were studied (42). In a pyomelanogenic strain of 
A. media WS, the hmgA gene was disrupted by an insertion of a different gene in the 
opposite orientation (18). Additionally, in a Burkholderia cenocepacia pyomelanogenic 
CF clinical isolate, a single point mutation in hmgA resulted in an amino acid change 
from a glycine to an arginine at residue 378, and this mutation was conserved in three 
of four pigmented B. cepacia complex strains (27). The G378R mutation in B. 
cenocepacia was located in the iron cofactor binding region of HmgA, which could affect 
iron binding and subsequent enzyme function (27). The B. cenocepacia data 
corresponds with our results, in which the H330Y mutation in HmgADKN343 was located 
at one of the iron cofactor binding sites (Figure 3.3) and interfered with protein function, 
as indicated by a failure of HmgAH330Y to alleviate pyomelanin production when 
expressed in hmgA::tn (Figure 3.4B). 
Hpd, the enzyme responsible for the production of HGA from 4-
hydroxyphenylpyruvate during tyrosine catabolism, is very important in the production of 
pyomelanin because HGA is the pyomelanin precursor molecule. Transposon 
mutagenesis or deletion of hpd led to an abolishment of pyomelanin production in 
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several bacterial and fungal species including B. cenocepacia, L. pneumophila, P. 
aeruginosa, A. media WS, and A. fumigatus (5, 12, 18, 26, 27, 43), demonstrating the 
importance of Hpd in pyomelanin production. Our results showed that deletion of hpd in 
DKN343 abolished pyomelanin production (Figure 3.4A), which further demonstrated 
that the tyrosine catabolism pathway mediates pyomelanin production in this strain. 
P. aeruginosa has high levels of intrinsic and acquired antimicrobial resistance, 
which can make it difficult to treat infections. Resistance to antimicrobial agents is 
mediated by several mechanisms, including low outer membrane permeability which 
can prevent antimicrobials from entering the cell, several multi-drug efflux pumps that 
can extrude a broad range of compounds, chromosomally encoded β-lactamase which 
can inactivate β-lactam antibiotics, and biofilm formation (31). We therefore assayed 
different mechanisms to elucidate the resistance to NTBC observed in DKN343 
including target alteration, sequestration by Hpd homologs, outer membrane 
impermeability, and multi-drug efflux pumps. 
In our studies, no mutations in hpdDKN343 were identified, indicating that target 
alteration was not a source of reduced NTBC activity in DKN343. The hypothetical 
protein PA0242 was identified as a potential Hpd homolog (Figure 3.5A); deletion of 
PA0242, however, did not increase sensitivity to NTBC in pyomelanin producers (Figure 
3.5B), which indicates that PA0242 is likely not sequestering NTBC. Additionally, 
increasing outer membrane permeability with EDTA did not have an effect on NTBC 
sensitivity in DKN343 (Figure 3.6). 
We also tested the effects of the constitutively expressed multi-drug efflux pump 
MexAB-OprM on NTBC resistance via deletion of mexA. MexAB-OprM contributes to 
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intrinsic antimicrobial resistance in P. aeruginosa by extruding several classes of 
antibiotics, as well as dyes, detergents, organic solvents, fatty acid synthesis inhibitors, 
and homoserine lactone (44). This broad substrate specificity makes it possible that 
NTBC could be a substrate for the pump. Resistance to NTBC was mediated by 
MexAB-OprM, as indicated by the reduction in pyomelanin production in mexA mutants 
following treatment with reduced levels of NTBC relative to the parent strain (Figure 
3.7). Additionally, we observed that complementation of DKN343ΔmexA with His-MexA 
did not restore NTBC resistance to the levels seen in the parent strain DKN343, as 
indicated by reduced levels of pyomelanin production (Figure 3.7). This could be due to 
the possibility that MexAB-OprM is hyperexpressed in DKN343, and these induction 
conditions result in insufficient expression of His-MexA. It has been shown in several 
studies that mutations in the MexR, NalC, or NalD regulators of mexAB-oprM 
transcription result in hyperexpression of the operon in clinical isolates and laboratory 
strains of P. aeruginosa (45-49). Hyperexpression of MexAB-OprM would lead to 
increased levels of efflux pumps, contributing to the increased resistance to NTBC 
observed in DKN343 compared to hmgA::tn, and also explain the partial 
complementation of DKN343ΔmexA with His-MexA. 
In summary, DKN343 produces pyomelanin because of a point mutation in 
HmgA located at one of the residues involved in iron co-factor binding. This matches the 
results seen in several other studies where mutations in HmgA are responsible for 
pyomelanin production. We also determined that the multi-drug efflux pump MexAB-
OprM is responsible for much of the NTBC resistance observed in DKN343, and it is 
likely that efflux pumps would be a cause for NTBC resistance in other organisms. 
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Since many bacterial and fungal pathogens produce pyomelanin, inhibition of 
pyomelanin production is an attractive target for anti-virulence treatment. A recent study 
in L. pneumophila identified a compound that inhibited phenylalanine hydroxylase, 
which converts phenylalanine to tyrosine, and subsequently inhibited pyomelanin 
production (50). This study demonstrated that targeting other enzymes in the 
phenylalanine/tyrosine catabolism pathway may inhibit pyomelanin production in 
bacteria. Targeting phenylalanine hydroxylase may have limited effectiveness in the 
inhibition of pyomelanin production, as tyrosine can still be catabolized to the 
pyomelanin precursor HGA. Because NTBC inhibits a later step in the catabolic 
pathway, the use of both phenylalanine and tyrosine to synthesize pyomelanin is 
inhibited. While NTBC shows promise as an anti-virulence therapy, its effectiveness 
may be limited against an organism with a high level of pre-existing antibiotic resistance 
such as P. aeruginosa. Future studies focused on the prevalence of this resistance in 
pyomelanogenic microbes are required to determine the future applications of NTBC as 
an anti-virulence agent. 	
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Macrophage-based killing of pyomelanogenic 
Pseudomonas aeruginosa 
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4.1 Introduction 
 
 Pseudomonas aeruginosa is a Gram negative rod shaped bacterium that is found 
in diverse ecological environments including soil, water, plants, and animals (1). It is 
also an important opportunistic pathogen that causes acute and chronic infections in 
individuals who are compromised. Chronic P. aeruginosa infections are common in the 
lungs of cystic fibrosis (CF) patients, where the bacterium forms biofilms that are difficult 
to eradicate, leading to persistence of infection (2). Burn patients are also very 
frequently colonized by P. aeruginosa (3, 4), where the infection is acute. P. aeruginosa 
produces a variety of virulence factors that allow it to colonize a host and cause 
infection, including secreted proteins, toxins, and pigments (5). Pyomelanin is a reddish-
brown pigment produced by some strains of P. aeruginosa (6). 
Pyomelanin is derived from homogentisate during tyrosine catabolism and is 
produced when there is a defect in this pathway, either 1) through deletion or mutation 
of key genes, particularly hmgA that encodes homogentisate 1,2-dioxygenase, or 2) a 
reduction in the activity of enzymes in the lower part of the pathway (7-12). Pyomelanin 
has a variety of functions including resistance to oxidative and UV stress, electron 
transfer and metal reduction, iron uptake by the bacterial cell, and persistence during 
infection (10, 11, 13-20). 
During bacterial infections, phagocytic cells such as polymorphonuclear 
leukocytes (PMNs) and macrophages are recruited to the site of infection (21). These 
phagocytic cells have several functions that are involved in clearing the infection. 
Initially, they are involved in phagocytosis of the bacteria, where the bacteria are 
engulfed into phagosomes that acidify and mature into phagolysosomes (22). Reactive 
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oxygen species (ROS) are then produced to help bring about bacterial cell death in the 
phagolysosome (22). ROS production and release into the surrounding tissue leads to 
inflammation (23). Additionally, phagocytic cells are involved in the production and 
release of cytokines, which function in the recruitment of additional inflammatory cells to 
the site of infection (24). In individuals with CF increased PMN recruitment is associated 
with the release of ROS and proteolytic enzymes that damage tissue and cause 
prolonged inflammation in the lungs (23, 25, 26). 
Because one of the functions of pyomelanin is increased resistance to oxidative 
stress and studies have shown bacterial persistence during infection by pyomelanin 
producers, we wanted to determine the effects of pyomelanin on macrophage-based 
killing of P. aeruginosa. We hypothesized that if pyomelanin has a protective effect for 
the bacteria against ROS produced by macrophages, we would see increased survival 
of pyomelanin producing bacteria compared to pyomelanin non-producers during 
infection of macrophages. We used the RAW 264.7 murine macrophage-like cell line for 
our infection studies. 
 
4.2 Materials and Methods 
 
4.2.1 Bacterial growth conditions  
A list of bacterial strains and plasmids is found in Table 4.1. Bacterial strains 
were grown in LB broth or on LB plates supplemented with antibiotics were appropriate. 
Antibiotics were used at the following concentrations: gentamicin 10 µg ml-1 (E. coli) and 
50 µg ml-1 (P. aeruginosa); tetracycline 10 µg ml-1 (E. coli) and 75 µg ml-1 (P. 
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Table 4.1. Strains and plasmids used in this study. 
Strains Description Source 
P. aeruginosa PAO1 P. aeruginosa PAO1 (Iglewski 
strain) 
Carrie Harwood 
P. aeruginosa Δhpd In-frame deletion of hpd in 
PAO1, pyomelanin non-
producer 
This study 
P. aeruginosa ΔhmgA In-frame deletion of hmgA in 
PAO1, pyomelanin producer 
This study 
E. coli DH5α fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80 Δ(lacZ)M15 gyrA96 
recA1 relA1 endA1 thi-1 hsdR17 
New England Biolabs 
E. coli S17-1 TpR SmR recA thi pro hsdR- M+ 
RP4 2-Tc::Mu-Km::Tn7 λpir 
Strain for conjugating plasmids 
(27) 
RAW 264.7 Murine macrophage-like cell line ATCC 	
Plasmids Description Source 
pEX18Tc Suicide vector for making deletion 
mutants, TcR 
Carrie Harwood 
pEX19Gm Suicide vector for making deletion 
mutants, GmR 
Carrie Harwood 
Δhpd-pEX18Tc Fusion fragment for hpd deletion 
cloned into pEX18Tc at the BamHI 
and HindIII sites 
This study 
ΔhmgA-pEX19Gm Fusion fragment for hmgA deletion 
cloned into pEX19Gm at the EcoRI 
site, introduced HindIII site was lost 
during cloning 
This study 
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aeruginosa); chloramphenicol 5 µg ml-1. Strains were grown at 37°C unless otherwise 
indicated and stored at -80°C in 15% glycerol. 
 
4.2.2 Generation of deletion mutants  
 
In-frame deletion mutants of hpd and hmgA in P. aeruginosa PAO1 were 
constructed by splicing by overlap extension (SOE) PCR with PAO1 DNA as template. 
Primers are listed in Table 4.2. The in-frame fusions were sequenced to ensure no 
mutations were introduced. The deletion alleles were cloned into pEX19Gm or pEX18Tc 
and transformed into E. coli S17-1 for mating with P. aeruginosa. These constructs were 
introduced into P. aeruginosa by conjugation, and merodiploids were selected on 
chloramphenicol and tetracycline or gentamicin as appropriate. Resolution of the 
merodiploids was achieved through 10% sucrose counter selection. Following screening 
on tetracycline or gentamicin and sucrose, the deletions were confirmed by PCR. 
 
4.2.3 RAW 264.7 murine macrophage-like cell line growth conditions 
 
RAW 264.7 cells were routinely grown for assays in 25 or 75 cm2 cell culture 
flasks in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum, penicillin (100 U ml-1), and streptomycin (100 µg ml-1) at 37°C and 10% 
CO2. Cells were grown to 75 – 85% confluence before dissociation from cell culture 
flasks with TrypLE Express. Aliquots of RAW 264.7 cells from passages 2-5 of the initial 
stock cell culture were stored at -80°C in Recovery Cell Culture Freezing Medium and 
thawed as needed. RAW 264.7 cells were discarded after passage 15.
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Table 4.2. List of primers used in this study. 
Primer name Primer Sequence (5’ – 3’ )a 
Δhpd-up-For GTAGCGGATCCCGATGCCTGCCACCGGAC 
Δhpd -up-Rev GAGGCTGGCGGCAGCGGGACCGGCCTCCTCGTTGT
TC 
Δhpd -dn-For GAACAACGAGGAGGCCGGTCCCGCTGCCGCCAGCC
TC 
Δhpd -dn-Rev CGCCGAAGCTTGCCGCGGTGAAGCCGAGC 
ΔhmgA-up-For CTGGAATTCCCTACCCGACGTCGCGCC 
ΔhmgA -up-Rev CATGGGGTTATCTCCGTTGGAGGTTCATCTGAGGCC
TCCGGGGAG 
ΔhmgA -dn-For CTCCCCGGAGGCCTCAGATGAACCTCCAACGGAGAT
AACCCCATG 
ΔhmgA -dn-Rev CTGAAGCTTGGCTGTTGCTCAGGGTCAGG 
aRestriction enzyme sites are underlined.
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4.2.4 RAW 264.7 killing of intracellular bacteria 
 
The infection assay to determine RAW 264.7 killing of intracellular bacteria was 
modified from previously described procedures (28). RAW 264.7 cells were seeded 
(2x105 cells well-1) in 12-well cell culture plates and attached for 1 h. Overnight cultures 
of Δhpd and ΔhmgA bacterial strains were diluted in LB to multiplicity of infection (MOI) 
54.9 ± 7.0 and added to the wells containing attached RAW 264.7 cells to infect the 
cells. Infections were synchronized by centrifuging at 130 xg for 5 min, followed by 
incubation for 30 min at 37°C and 10% CO2. RAW 264.7 cells were washed 3 times with 
Dulbecco’s phosphate buffered saline lacking CaCl2 and MgCl2 (DPBS) before fresh 
DMEM containing 0 or 500 µg ml-1 gentamicin was added. Infected RAW 264.7 cells 
were incubated for 2 h, washed 3 times with DPBS, and lysed with 0.1% Triton X-100. 
Cell lysates were plated on LB to determine bacterial survival. Bacterial killing by RAW 
264.7 cells was quantified for each bacterial strain, MOI, and gentamicin condition in 
triplicate for three independent assays. The recovered bacterial CFU ml-1 was 
normalized to percentage of inoculum to determine total RAW 264.7 associated bacteria 
(0 µg ml-1 gentamicin) and intracellular bacteria (500 µg ml-1 gentamicin). Percentage of 
intracellular bacteria was calculated relative to total cell-associated bacteria. To compile 
results from three independent assays, viable bacteria or percentage of intracellular 
bacteria was averaged for each strain and gentamicin condition. Statistical analysis was 
performed by ANOVA, followed by Tukey HSD post-hoc analysis using R (version 
3.2.4). 
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4.2.5 RAW 264.7 bacterial association and killing of bacteria over time 
 
The time course assay to determine RAW 264.7 bacterial association and killing 
after a 15 or 30 minute infection time was modified from previously described 
procedures (29). RAW 264.7 cells suspended in DMEM lacking antibiotics were 
dispensed into microfuge tubes (1x106 cells per 900 µl). Overnight cultures of Δhpd and 
ΔhmgA bacterial strains were diluted in LB to MOI 57.2 ± 4.2 (15 minute infection) or 
MOI 58.3 ± 2.8 (30 minute infection) and added to the RAW 264.7 cells to obtain a total 
volume of 1 ml. Infections occurred for 15 or 30 min at 37°C with rotation. After 
infection, samples were incubated at 37°C with rotation and aliquots were taken every 
30 min (starting with T=0 min after infection) for viable counts to determine RAW 264.7 
total bacterial cell association and killing over time. At each time point, the entire sample 
was centrifuged at 1500 rpm for 5 min and the pellet was resuspended in an equal 
volume of fresh DMEM without antibiotics to remove bacteria that were not associated 
with RAW 264.7 cells. An aliquot of each sample was mixed with water to lyse RAW 
264.7 cells, followed by serial dilution in water. Diluted samples were spotted in triplicate 
on LB to quantify the number of viable bacteria associated with RAW 264.7 cells. The 
recovered bacterial CFU ml-1 for each assay was calculated as a percentage of the 
inoculum. The percent bacterial survival over time was calculated by dividing the 
number of viable bacteria at any given time point by the viable bacteria at the beginning 
of the incubation (T=0 min). Total bacterial association with RAW 264.7 cells at 0 min 
was used to determine the effect of infection time on bacterial association with RAW 
264.7 cells. Three independent assays were tested for 15 and 30 minute infection times. 
To compile results from three independent assays, viable bacteria or percent survival 
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was averaged for each strain at each time point. Statistical analysis was performed by 
ANOVA, followed by Tukey HSD post-hoc analysis using R (version 3.2.4). 
 
4.3 Results 
 
4.3.1 RAW 264.7 cell killing of intracellular bacteria is similar for pyomelanin 
producers and non-producers. 
The P. aeruginosa pyomelanin producer ΔhmgA and the non-producer Δhpd 
were tested for survival in the RAW 264.7 murine macrophage-like cell line. A 30 minute 
infection was followed by incubation with and without gentamicin for 2 hours (Figure 
4.1). The CFU ml-1 of viable bacteria was normalized as a percentage of the bacterial 
inoculum. The viable bacteria for ΔhmgA isolated from RAW 264.7 cells was 
approximately two fold higher than the viable bacteria for Δhpd isolated for both total 
cell-associated bacteria (those exposed to no gentamicin) and for intracellular bacteria 
(those exposed to gentamicin). The difference between total cell-associated bacteria 
and between intracellular bacteria when comparing both strains was not statistically 
significant (Figure 4.1). These results indicated that ΔhmgA may associate slightly 
better with the RAW 264.7 cells than Δhpd, which could be due to the pyomelanin 
produced by this strain, as ΔhmgA and Δhpd are isogenic to each other. Within a strain, 
there was a fairly large difference between total cell-associated bacteria and 
intracellular bacteria when viable bacteria were examined (Figure 4.1); this difference, 
however, was not statistically significant for either strain.
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Figure 4.1. RAW 264.7 killing of intracellular bacteria is similar for pyomelanin producers and non-
producers. Viable bacteria as percent of inoculum was calculated for total cell-associated (no 
gentamicin treatment) and intracellular (gentamicin treated) bacteria. ΔhmgA had a higher percentage 
of viable bacteria relative to inoculum than Δhpd, which indicated that more of the pyomelanin 
producing ΔhmgA bacteria associated with the RAW 264.7 cells. The bacterial MOI was 54.9 ± 7.0. 
Three independent assays were tested. Blue bars, Δhpd; red bars, ΔhmgA. ANOVA followed by Tukey 
HSD post-hoc analysis showed no significant differences between the strains and gentamicin 
treatment. 
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 When the percent of intracellular bacteria was calculated relative to the total cell-
associated bacteria, there was a very slight difference between ΔhmgA (35.4% ± 5.8%) 
and Δhpd (37.5% ± 7.1%) in RAW 264.7 cells; this difference was not statistically 
significant. Additionally, the difference between total cell-associated bacteria and 
percent of intracellular bacteria was significant for both strains (p<0.001). These results 
indicated that the pyomelanin produced by ΔhmgA did not provide protection from RAW 
264.7 killing of the intracellular bacteria under these assay conditions. 
 
4.3.2 Association of bacterial pyomelanin producers and non-producers with 
RAW 264.7 cells is similar after infection for 15 or 30 minutes. 
RAW 264.7 cells exposed to ΔhmgA and Δhpd for 15 or 30 minute infections 
showed slight differences in bacterial association with the cells (Figure 4.2). The viable 
bacterial CFU ml-1 that was isolated for each strain was normalized to percentage of 
bacterial inoculum. The results showed that there were slightly higher percentages of 
RAW 264.7-associated bacteria for both ΔhmgA and Δhpd after the 30 minute infection 
compared to the 15 minute infection (Figure 4.2); however, this slight increase in 
bacterial association was not statistically significant for either bacterial strain. The 
slightly higher association of bacteria with RAW 264.7 cells in the 30 minute infection is 
likely due to the increased time. There was little difference, however, between ΔhmgA 
and Δhpd association with RAW 264.7 cells within either infection time, and what little 
difference was present was not statistically significant (Figure 4.2). Overall, these 
results indicated that pyomelanin did not appear to play a role in bacterial association 
with the RAW 264.7 cells under the conditions tested.
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Figure 4.2. Association of bacterial pyomelanin producers and non-producers with RAW 264.7 cells is 
similar after infection for 15 or 30 minutes. Viable bacteria as percentage of inoculum was calculated 
for each strain and condition. A 30 minute infection showed slightly higher percentages of RAW 264.7-
associated bacteria than a 15 minute infection. The bacterial MOI for the 15 minute infection was 57.2 
± 4.2. The bacterial MOI for the 30 minute infection was 58.3 ± 2.8. Three independent assays were 
tested for each infection time. Blue bars, Δhpd; red bars, ΔhmgA. ANOVA followed by Tukey HSD 
post-hoc analysis showed no significant differences between the strains and infection times. 
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4.3.3 Bacterial killing by RAW 264.7 cells over time is similar for pyomelanin 
producers and non-producers. 
The time course assay for RAW 264.7 bacterial killing was determined following 
a 15 or 30 minute infection with ΔhmgA and Δhpd (Figure 4.3). The CFU ml-1 for viable 
bacteria was normalized to percentage of bacterial inoculum. Most of the bacterial killing 
by RAW 264.7 occurred in the first 30 to 60 minutes after infection. After both the 15 
and 30 minute infections, the ΔhmgA strain generally had a slightly higher percentage of 
viable bacteria associated with RAW 264.7 cells than the Δhpd strain (Figures 4.3A and 
4.3C); this difference was not statistically significant. These results could be indicative of 
a slightly higher association of ΔhmgA with RAW 264.7 cells during infection, which 
could be due to the presence of pyomelanin. This observation also corresponds with the 
data from figure 4.1 in which ΔhmgA had an approximately two fold higher percentage 
of viable bacteria associated with RAW 264.7 cells compared to Δhpd.  
The bacterial percent survival over time was slightly higher for ΔhmgA compared 
to Δhpd after both the 15 and 30 minute infection times, but the differences between the 
two strains was not statistically significant (Figures 4.3B and 4.3D). These results 
indicated that the presence of pyomelanin in the ΔhmgA strain conferred very little 
survival advantage, if any, during killing by RAW 264.7 cells under the tested conditions. 
Additionally, increasing or decreasing the infection time had little effect on bacterial 
survival during the RAW 264.7 killing assay since there were few differences between 
the bacterial survival curves after different infection times.
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Figure 4.3. Time course of bacterial killing by RAW 264.7 cells following a 15 (A and B) or 30 (C and 
D) minute infection is similar for pyomelanin producers and non-producers, regardless of infection 
period duration. A) The ΔhmgA strain showed a higher percentage of viable bacteria relative to the 
inoculum concentration than the Δhpd strain after the 15 minute infection. B) The percent survival of 
bacteria isolated from RAW 264.7 cells was slightly higher for ΔhmgA than for Δhpd after the 15 
minute infection. Percent survival was calculated from the number of viable bacteria at each time point 
relative to 0 minutes. C) The ΔhmgA strain showed a slightly higher percentage of viable bacteria 
relative to the inoculum concentration than the Δhpd strain at every time point except 0 minutes after 
the 30 minute infection. D) The percent survival of bacteria isolated from RAW 264.7 cells was slightly 
higher for ΔhmgA than for Δhpd after the 30 minute infection. Percent survival was calculated from the 
number of viable bacteria at each time point relative to 0 minutes. Blue diamonds, Δhpd; red squares, 
ΔhmgA. The bacterial MOI for the 15 minute infection was 57.2 ± 4.2. The bacterial MOI for the 30 
minute infection was 58.3 ± 2.8. Three independent assays were tested for each infection time. 
ANOVA followed by Tukey HSD post-hoc analysis showed no significant difference between strains. 
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4.4 Discussion 
 
 It has previously been reported that pyomelanogenic P. aeruginosa showed 
increased persistence in mouse models of infection compared to non-pyomelanogenic 
strains (11, 20). Melanin also scavenged superoxide anion produced by macrophages 
(30). Additionally, pyomelanin producing Burkholderia cenocepacia showed reduced 
trafficking to RAW 264.7 lysosomes compared to a non-pigmented strain (14). These 
studies all suggested that pyomelanin plays a role in bacterial persistence during 
infection of phagocytes. We therefore decided to investigate the role of pyomelanin 
produced by P. aeruginosa in bacterial killing by the murine macrophage-like cell line 
RAW 264.7. 
 Our results for RAW 264.7 killing of P. aeruginosa showed that pyomelanin did 
not provide a survival advantage for the bacteria upon infection of RAW 264.7 cells. 
Despite testing bacterial survival under several experimental conditions, we found that 
there was very little, if any, survival advantage from producing pyomelanin by the 
bacteria. In the RAW 264.7 killing assay, the percentage of surviving intracellular 
bacteria after a 30 minute infection and subsequent 2 hour treatment with gentamicin 
was similar for both pyomelanin producers and non-producers (Figure 4.1). Percent 
survival was also similar for the pyomelanin producer ΔhmgA and the non-producer 
Δhpd in the time course killing assay (Figure 4.3B and 4.3D). These results correlate 
with experiments done in Legionella pneumophila which found that pyomelanin 
production had no role in intracellular survival of the bacterium in the host organism 
Hartmannella vermiformis (31). 
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Interestingly, the total percentage of cell-associated ΔhmgA was generally higher 
than that for Δhpd when they were normalized to the amount of inoculum, but the 
difference between the strains was not statistically significant (Figures 4.1 and 4.3). This 
result indicated that pyomelanin producers may associate better with RAW 264.7 cells 
than pyomelanin non-producers. A potential explanation for this observation is that the 
pyomelanin producers may be slightly more resistant to phagocytosis than non-
producers, which could allow the pyomelanogenic bacteria to associate with the RAW 
264.7 cells, but not be phagocytized, resulting in higher numbers of cell-associated 
bacteria. In the fungal species Penicillium marneffei and Paracoccidioides brasiliensis, 
melanized cells exhibited reduced phagocytosis by macrophages (32, 33). It should be 
noted, however, that these organisms produce L-DOPA melanin, and the differences 
between pyomelanin and L-DOPA melanin may be important when considering these 
results. 
Additionally, we found that there was little difference in bacterial cell association 
with the RAW 264.7 cells between the ΔhmgA and Δhpd strains after a 15 or 30 minute 
infection (Figure 4.2). Although bacterial cell association was slightly higher after the 30 
minute infection compared to the 15 minute infection, the difference was not statistically 
significant. This difference was likely due to having increased time with which to 
associate with RAW 264.7 cells in the 30 minute infection. Within an infection time, 
there was no significant difference between ΔhmgA and Δhpd association with RAW 
264.7 cells. 
One of the differences between our studies and previously published studies is 
the bacterial strains that were used. In the mouse models of infection, P. aeruginosa 
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PA14 was used (11, 20), while we used P. aeruginosa PAO1, which is less virulent than 
PA14 (34). The difference in virulence between PA14 and PAO1 could contribute to the 
lack of protection by pyomelanin that was seen in our studies of RAW 264.7 killing of 
bacteria. 
Another factor that could have affected our results is that the bacterial strains 
were diluted in LB for our experiments and it is unlikely that additional pyomelanin would 
be produced during the duration of the assay. Therefore, the soluble pyomelanin 
produced by the ΔhmgA strain was diluted, which could have resulted in decreased 
protection for that strain in the RAW 264.7 killing assays. Cell surface associated 
pyomelanin would have provided most of the protection for the bacteria in our assays. 
 In the future, different methods of examining RAW 264.7 killing of P. aeruginosa 
may be investigated. First, it may be possible to quantify RAW 264.7 associated 
bacterial cells, as well as bacterial uptake, via fluorescence microscopy (35). This 
method may reveal differences in uptake or cell association between pyomelanin 
producers and non-producers that could not be determined via viable counts. Flow 
cytometry could also be used to quantify phagocytosis of pyomelanin producers and 
non-producers. It is also possible to investigate bacterial survival in RAW 264.7 cells via 
live/dead staining (35). This technique may give us a better understanding of how many 
bacteria are taken up and killed by RAW 264.7 cells during infection and would be 
independent of culturing bacteria on a plate for viable counts. Finally, we could 
investigate the ability of pyomelanin produced by bacteria to scavenge ROS generated 
by RAW 264.7 cells (30). This assay could reveal differences in scavenging of ROS in 
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pyomelanin producers and non-producers and would contribute to our understanding of 
how the RAW 264.7 cells may be killing the bacteria. 
It is possible that our experimental conditions were not ideal to determine if 
pyomelanin provides protection from macrophage-based killing of bacteria. For 
example, a different macrophage cell line may have been more appropriate for our 
experiments. Additionally, infection experiments in cell culture do not always mimic the 
conditions in an animal infection, so animal based infection assays could give a different 
result. The previous studies that determined that pyomelanin producers had increased 
persistence during infection were performed in mouse models of infection (11, 20). 
Therefore, performing our infection studies in mice may be a more appropriate 
approach to studying the effects of pyomelanin on bacterial survival during infection. Of 
course, even after using alternative methods to examine bacterial killing by 
macrophages or using mouse models of infection, it is possible that the results could 
correspond with our results and show no protective effect for pyomelanin during 
infection. If that happens, it suggests that the results presented in this study are valid 
and not due to experimental error or improper test conditions. 
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 In this work, I have investigated mechanisms for pyomelanin production in clinical 
isolates of Pseudomonas aeruginosa. Pyomelanin is an extracellular, reddish-brown 
pigment derived from homogentisate (HGA), which is produced via the 
phenylalanine/tyrosine catabolism pathway (1, 2). Previous studies have shown that 
point mutations or chromosomal deletions in hmgA, which encodes homogentisate 1,2-
dioxygenase, result in the accumulation of HGA and frequently pyomelanin production 
(3, 4). My work showed that the pyomelanogenic P. aeruginosa clinical isolate PA1111, 
which was isolated from an acute infection in a burn patient, had a chromosomal 
deletion of hmgA (Chapter 2) (5, 6). A second pyomelanogenic clinical isolate, DKN343, 
which was isolated from a sputum sample, had previously been reported to have no 
mutations in hmgA (7); I identified two mutations in hmgA for this strain, however, and 
determined that the H330Y mutation in the iron cofactor binding site of HmgA was 
responsible for pyomelanin production in this strain (Chapter 3). In addition, by deleting 
hpd, which encodes the 4-hydroxyphenylpyruvate dioxygenase that produces HGA, I 
determined that the phenylalanine/tyrosine catabolism pathway is required for 
pyomelanin production and that inactivation of HmgA was the sole cause of pyomelanin 
production in DKN343 (Chapter 3). While these results are in contrast to the previously 
published study on DKN343, these results are ultimately unsurprising because several 
pyomelanogenic bacterial species, including Vibrio cholerae, Aeromonas media, and 
Burkholderia cenocepacia have deletions, insertions, and point mutations in hmgA, 
respectively, as causes for pyomelanin production (8-10). 
 The Hpd inhibiting compound 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
cyclohexanedione (NTBC) has been proposed as a treatment for microbial infections by 
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pyomelanin producers (11). NTBC inhibits Hpd by binding irreversibly to the ferrous 
metal center in the active site of the enzyme (12). Because NTBC binds to Hpd, which 
is responsible for producing the pyomelanin precursor molecule HGA, pyomelanin 
production should be inhibited. I have investigated the effects of NTBC on pyomelanin 
production in clinical isolates of P. aeruginosa, and determined that NTBC reduced 
pyomelanin production in a dose dependent manner in both PA1111 and DKN343 
(Chapters 2 and 3); DKN343, however, was more resistant to NTBC than PA1111. 
Studies of NTBC resistance in DKN343 revealed that the constitutively active multi-drug 
efflux pump MexAB-OprM was responsible for the inherent resistance to NTBC seen in 
that strain (Chapter 3).  
I also investigated the effects of NTBC on sensitivity to oxidative stress because 
one of the functions of pyomelanin is resistance to oxidative stress (4, 13, 14). 
Treatment of PA1111 with NTBC resulted in increased sensitivity to H2O2 oxidative 
stress compared to the untreated strain (Chapter 2) (6). Additionally, I tested the 
antibiotic sensitivity of PA1111 with and without NTBC to determine if reducing 
pyomelanin production had an effect on minimum inhibitory concentrations (MICs). This 
study was important because conflicting data on the effects of pyomelanin on antibiotic 
MICs has been published. Various reports in different microbial species have stated that 
antibiotic MICs were higher in pyomelanogenic organisms, that pyomelanin had no 
effect on MICs, and that pyomelanin producers were more sensitive to antibiotics (4, 15-
21). My work showed that a reduction in pyomelanin production with NTBC had no 
effect on aminoglycoside MICs (Chapter 2) (6). This demonstrated that NTBC could 
possibly be used in conjunction with antibiotics. 
		 119 
 Finally, I investigated macrophage-based killing of pyomelanogenic and non-
pyomelanogenic strains of P. aeruginosa. Pyomelanin was found to be involved in 
persistence of P. aeruginosa in mouse models of infection (4, 22). Melanin also 
scavenged superoxide anion produced by macrophages (23). In B. cenocepacia, 
pyomelanogenic strains showed reduced trafficking to lysosomes than non-pigmented 
strains (14). In my studies of macrophage-based killing of P. aeruginosa, I used the 
RAW 264.7 murine macrophage-like cell line. My results showed that the 
pyomelanogenic strain (ΔhmgA) showed little difference in bacterial survival during 
RAW 264.7 infection compared to the non-pyomelanogenic strain (Δhpd) under different 
test conditions (Chapter 4). A variety of factors could have impacted my results, 
including the use of P. aeruginosa PAO1 instead of the more virulent strain PA14 that 
was used in the mouse studies, dilution of extracellular pyomelanin in the assay, and 
the infection assay protocol itself. It is possible that different test or quantification 
conditions would have been more appropriate for these studies, such as a different way 
to quantify bacterial viability, a different macrophage cell line, or using a mouse model 
of infection. 
 In summary, my work provided some data for the potential development of NTBC 
as a therapeutic agent for treating pyomelanogenic microbial infections. By elucidating 
mechanisms of pyomelanin production in clinical isolates of P. aeruginosa and testing 
NTBC sensitivity on those strains, I was able to 1) determine if pyomelanin production 
was mediated by Hpd and 2) determine if there were any inherent mechanisms of 
NTBC resistance present in those strains. My studies showed that the clinical isolates 
PA1111 and DKN343 were more resistant to NTBC than the pyomelanogenic laboratory 
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strain hmgA::tn, and resistance to NTBC in DKN343 was mediated by the MexAB-OprM 
multi-drug efflux pump. It is possible that other pyomelanogenic organisms could have 
similar mechanisms for NTBC resistance. NTBC treatment, however, rendered PA1111 
more sensitive to H2O2 oxidative stress than the untreated strain. Targeting pyomelanin 
for anti-virulence treatment is attractive because there are many pathogenic bacteria 
and fungi that produce this pigment. NTBC does show some promise as an anti-
virulence agent, but its effectiveness may be limited in organisms with high levels of 
antimicrobial resistance such as P. aeruginosa. Therefore, future studies should focus 
on the prevalence of NTBC resistance in other pyomelanogenic organisms to determine 
the future applications of NTBC as an anti-virulence therapy. 
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